Evaluation and research on antimicrobial stewardship\u2019s Effect on Clostridium difficile (ERASE C. difficile) Project by Boston University. School of Public Health. et al.
 
Evaluation and Research on 
Antimicrobial Stewardship’s Effect on 
Clostridium difficile (ERASE C. difficile) 
Project  
Toolkit for Reduction of Clostridium difficile Through 
Antimicrobial Stewardship 
Prepared for: 
Agency for Healthcare Research and Quality 
U.S. Department of Health and Human Services 
540 Gaither Road 
Rockville, MD 20850 
www.ahrq.gov 
 
Centers for Disease Control  
Atlanta, GA 
1600 Clifton Road 
Atlanta, GA 30333 
www.cdc.gov 
 
AHRQ ACTION Contract No. HHSA290200600012i TO10 
 
Prepared by: 
Boston University School of Public Health  
Montefiore Medical Center  
Greater New York Hospital Association/United Hospital Fund 
 




Boston University School of Public Health (BUSPH) 
Carol VanDeusen Lukas, Ed.D., BUSPH and Center for Organization, Leadership, and 
Management Research, Department of Veterans Affairs 
Elisa Koppelman, M.S.W., BUSPH and Center for Health Quality, Outcomes, and Economic 
Research, Department of Veterans Affairs 
Montefiore Medical Center 
Brian Currie, M.D., M.P.H., Vice President and Medical Director for Research  
Belinda Ostrowsky, M.D., M.P.H., Director of Antimicrobial Stewardship Program 
Shakara Brown, M.P.H., Data Analyst, Antimicrobial Stewardship Program 
Paul Meissner, M.S.P.H., Director, Research Program Development, Office of the Medical 
Director for Research 
Yi Guo, Pharm.D., Antimicrobial Stewardship Program 
Philip Chung, Pharm.D., Antimicrobial Stewardship Program 
Claire Brown, M.D., Former Infectious Diseases Fellow  
Greater New York Hospital Association (GNYHA)/United Hospital Fund (UHF) 
Zeynep Sumer, M.S., Vice President of Regulatory and Professional Affairs, GNYHA 
Cynthia Araujo, Project Manager, GNYHA 
Rafael E. Ruiz, Ph.D., Director, Outcomes Research, GNYHA 
Hillary S. Jalon, M.S., Director, Quality Improvement, UHF 
Agency for Healthcare Research and Quality Contributors 
Katherine Crosson, M.P.H., Center for Quality Improvement and Patient Safety (retired) 
James I. Cleeman, M.D., Center for Quality Improvement and Patient Safety 
Darryl T. Gray, M.D., Sc.D., FAHA, Center for Quality Improvement and Patient Safety 
Centers for Disease Control and Prevention 
Carolyn Gould, M.D., M.S.C.R., Division of Healthcare Quality Promotion 
This project was funded under Contract Number HHSA290200600012i, TO #10, from the 
Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human 
Services. The opinions expressed in this document are those of the authors and do not 




The development of this toolkit was facilitated by the participation and assistance of 
antimicrobial stewardship teams at 10 medical centers:  Beth Israel Medical Center - Beth 
Israel Brooklyn (formerly known as the King’s Highway Division) and The Milton and 
Carroll Petrie Division; Bronx-Lebanon Hospital Center; Montefiore Medical Center - The 
North Division, The Henry and Lucy Moses Division, and The Jack D. Weiler Hospital of the 
Albert Einstein College of Medicine; North Shore-Long Island Jewish Health System - Glen 
Cove Hospital and Southside Hospital; St. Luke’s-Roosevelt Hospital Center - St. Luke’s 
Hospital and Roosevelt Hospital. 
This document is in the public domain and may be used and reprinted without permission 
except those copyrighted materials that are clearly noted in the document. Further 
reproduction of those copyrighted materials is prohibited without the specific permission 




Overview .................................................................................................................................................................. 1 
What is antimicrobial stewardship and how can it help us in reducing C. difficile? ............. 1 
How can this toolkit help us? ...................................................................................................................... 2 
How do we use the toolkit? ......................................................................................................................... 2 
How was the toolkit developed? ............................................................................................................... 3 
Questions To Consider in Developing an Antimicrobial Stewardship Program To Reduce C. 
difficile Infection.................................................................................................................................................... 5 
1. Is our organization ready for an ASP to reduce C. difficile? ........................................................ 5 
1.1. Do we have the appropriate ASP foundation on which to build? ................................... 5 
1.2. What do we need to do before we begin to use our ASP to target C. difficile? .......... 6 
2. How do we determine which interventions for reducing C. difficile to implement? ......11 
2.1. What is the institutional risk assessment approach? How can it help us? ...............11 
2.2. How do we conduct a time-limited internal case-control study for C. difficile? 
What are some of the challenges? ..........................................................................................13 
2.3. What methods can we use to review the use of potential target antibiotics for 
intervention activities? ..............................................................................................................16 
2.4. What factors do we need to consider in choosing interventions? ...............................17 
2.5. How do we implement the intervention? ..............................................................................17 
3. How do we monitor the intervention and measure outcomes? .............................................19 
3.1. How do we measure rates of C. difficile over time? ...........................................................19 
3.2. How do we obtain, measure and analyze antibiotic data? ..............................................21 
3.3. How can we monitor the intervention and why should we? ..........................................22 
3.4. What other processes do we need to monitor and measure? ........................................23 
3.5. How do we analyze financial data? ..........................................................................................23 
3.6. How do we assess the overall impact of our interventions? How do we decide 
which interventions have been the most successful (and which interventions 
were not) and why? .....................................................................................................................24 
4. How do we sustain the ASP for reducing C. difficile over time? ..............................................25 
Will our current ASP staffing work on an ongoing basis?........................................................26 
What is the plan for ongoing measurement and feedback? ....................................................26 
What ongoing organizational support will we need to keep the new ASP practices in 
place? ................................................................................................................................................26 
How do we keep the ASP efforts relevant and a continued focus?.......................................26 
References .............................................................................................................................................................27 
Summary of Tools and Resources ................................................................................................................28 
  
vi 
Tools and Resources 
Ø 1E TOOL: Assessment of Current Antimicrobial Stewardship Program Elements .............. 30 
Ø 1F Tool: Common Evidence-Based Infection Prevention Measures .......................................... 31 
Infection Control and Prevention for C. difficile Infection: What Health Care Workers, 
Patients, and Visitors Can Do ........................................................................................................................ 31 
Ø 1G TOOL: Assessing Leadership Support ............................................................................................. 32 
Ø 1H TOOL: Stakeholder Analysis ............................................................................................................... 33 
Ø 1I TOOL: Survey of Staff Attitudes Toward ASP and Current Practices ................................... 34 
Ø 1K TOOL: Developing the Business Case .............................................................................................. 37 
Ø 1L TOOL: Assessing Resource Needs ..................................................................................................... 38 
Ø 1M RESOURCE: Potential barriers to implementing an ASP ......................................................... 39 
Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship 
Interventions ....................................................................................................................................................... 41 
Ø 2B RESOURCE: A Comparison of Antibiotic Data Sources ............................................................. 43 
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use ................................................. 44 
Ø 2D RESOURCE: Does Choice of Control Group Affect the Association of Antibiotics With 
Clostridium difficile-Associated Diarrhea? ................................................................................................ 46 
Ø 2E RESOURCE: Sample Tracking and Summary Forms for Case-Control Study ................... 47 
Ø 2F RESOURCE: Comparison of Potential Antimicrobial Stewardship Interventions, With 
an Emphasis on Reducing C. difficile1 ......................................................................................................... 50 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With Suggested 
Process/Monitoring, Antibiotic Use, and Additional Measures of Impact ................................... 52 
Ø 2H RESOURCE: Specific Intervention Examples From ERASE C.  difficile Project ................ 54 
Ø 3G/3H RESOURCES: Environmental Cleaning and Infection Prevention Checklists ........... 56 
Ø 4A TOOL: How Do We Sustain ASP for Reducing C difficile Over Time? ................................... 59 
Ø 4B TOOL: UTI Guidelines Form ................................................................................................................ 62 
Ø 4C TOOL: Pipercillan/Tazobactam De-Escalation Form................................................................. 65 
Ø 4D TOOL: Medication Use Evaluation Template ................................................................................ 68 
 
Resources 1A, 1B, 1C, 1D, 3A, 3B, 3C, 3D, 3E, and 3F are available online through links 
found in the sections that refer to them. 
 
1 
Toolkit on Antimicrobial Stewardship To Reduce C. difficile Infection 
Overview 
Clostridium difficile infection (C. difficile) is a serious public health problem that has 
recently increased in both incidence and severity. Centers for Disease Control and 
Prevention (CDC) surveillance data show that U.S. hospital discharges with C. difficile 
doubled between 2000 and 20031 and rates are highest in the northeastern United States.2 
Persons over age 65 years have been most affected, but recent changes in epidemiology 
suggest that lower risk populations, including healthy postpartum women and community 
dwellers with no recent healthcare contact or antimicrobial exposures, may also be 
affected.3 
Further, there are indications of recent increases in the severity of C. difficile, including 
increased complications and C. difficile-related mortality. In addition to advanced age, the 
major risk factors for C. difficile are exposure to antimicrobials and hospitalization. Studies 
have found major costs associated with C. difficile, such as longer inpatient lengths of stay, 
and a significant increase in costs both for inpatient care and at 180 days after the initial 
hospitalization when the C. difficile occurred.4  
Taking steps to reduce C. difficile is a major health and public health imperative. Twenty-
seven States and the District of Columbia now require reporting of healthcare-associated 
infections to the National Healthcare Safety Network (NHSN).5 Moreover, CDC’s NHSN 
created a reporting module for C. difficile as part of its Patient Safety Component to 
encourage infection surveillance or laboratory-identified event reporting across hospitals 
nationwide.6  
What is antimicrobial stewardship and how can it help us in reducing C. difficile?  
Significant progress has been made in working to control C. difficile through targeted 
strategies such as infection prevention measures and environmental cleaning using a 
hypochlorite-based solution.7 However, particularly as new resistant C. difficile strains 
emerge, the problem persists and additional strategies are needed. Antimicrobial 
stewardship targeted to C. difficile reduction shows promise as a complementary strategy 
for addressing the problem of C. difficile, because inappropriate antibiotic use may 
contribute to increased rates of C. difficile.  
An antimicrobial stewardship program (ASP) is a systematic approach to developing 
coordinated interventions to reduce overuse and inappropriate selection of 
antibiotics, and to achieve optimal outcomes for patients in cost-efficient ways. 
Through both monitoring and, when necessary, altering current antimicrobial prescribing 
practices, antimicrobial stewardship has been shown to improve patient care, reduce 
antimicrobial use, reduce antimicrobial resistance, and reduce pharmacy, and overall 
hospital operating costs.8 
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How do we use the toolkit? 
This toolkit is organized by four major questions and multiple supporting 
questions that will guide you through the full process of developing, 
implementing, and sustaining an ASP for C. difficile. The four questions are:  
1. Is our organization ready for an ASP to assist with C. difficile reduction 
efforts?  
2. How do we determine which interventions for reducing C. difficile to 
implement?  
3. How do we monitor the intervention and measure outcome?  
4. How do we sustain the ASP for reducing C. difficile over time? 
Each question has detailed discussion of the issues to be considered and 
references to tools and resources that will support the stewardship initiative. 
Tools and other resources are highlighted by a symbol: Ø.  
How can this toolkit help us?  
The aim of this toolkit is to assist hospital staff and leadership in developing an effective 
ASP with the potential to reduce C. difficile. It responds to the challenge facilities face as 
they translate guidelines into practice, in this case the implementation of an ASP. The 
toolkit: 
 Is designed as a companion to the Antimicrobial Stewardship Program toolkit 
developed by the Greater New York Hospital Association (GNYHA) and the United 
Hospital Fund (UHF) for the New York State Department of Health, which supports the 
basic development and implementation of antimicrobial stewardship. The New York 
toolkit follows the Roadmap to Stewardship shown in Figure 1. This new toolkit 
assumes that your hospital already has components that make up the foundation for an 
ASP from which to launch the ASP targeted to C. difficile reduction.  
 Is designed to help hospitals consider the organizational changes and resources 
needed to create and sustain an effective ASP for reducing C. difficile. The toolkit covers 
the full planning and implementation process from deciding to make changes to 
monitoring sustainability. While all the steps outlined here are important, some 
sections may be more relevant than others, depending on whether your hospital has an 
ASP framework on which to build and how you tailor your strategies and 
implementation to your needs, structures, and culture.  
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How was the toolkit developed? 
This toolkit was developed under a contract from the Agency for Healthcare Research and 
Quality (AHRQ) through its Accelerating Change and Transformation in Organizations and 
Networks (ACTION) initiative. Boston University School of Public Health (BUSPH) 
collaborated with Montefiore Medical Center (MMC) and GNYHA together with UHF to 
implement and evaluate ASP interventions to reduce C. difficile. The team worked with a 
collaborative of 10 New York hospitals that included 6 intervention sites and 4 
nonintervention sites.  
Despite the inability to demonstrate an association with reduced C. difficile rates in the time 
available, this project had many measured and unmeasured benefits. Among them, the 
project provided for growth and development of ASP infrastructures at each intervention 
site, measurable decreases in prescribing of target antibiotics at intervention facilities, and 
potential reduction of C. difficile with future ASP activities or with longer timeframes. The 
toolkit incorporates lessons learned from the experiences of the intervention hospitals, 
including facilitators of and barriers to building successful stewardship to reduce the use of 
antibiotics associated with high rates of C. difficile.
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Figure 1. GNYHA/UHF Roadmap to Antimicrobial Stewardship  
Source: Antimicrobial stewardship toolkit. New York, NY: Greater New York Hospital Association/United 
Hospital Fund; 2011. Available at: www.gnyha.org/antimicrobial/toolkit. 
Strategies 
1. Develop or update antibiogram 
2. Develop guidelines (e.g., care path) for diagnosis, 
treatment, and duration of antibiotic therapy and 
other interventions to treat infections 
3. Indentify dose optimization strategies 
4. Provide guidelines for parenteral to oral conversion 
5. Create formulary decisions, including antibiotic 
restrictions 
6. Develop policy/guidelines to streamline/de-escalate 
therapy 
7. Develop antimicrobial order forms with algorithms 
for common entities 
8. Provide continuous prospective review with 
feedback and interventions 
9. Communicate recommendations via chart stickers, 
notes, or face-to-face 
Scenarios and Strategies Used 
 Overtreatment of asymptomatic 
bacteriuria-Strategies 2, 7, 8, and 9 
 Patients on broad-spectrum antibiotics–
Strategies 2 , 6, 8, and 9 
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Questions To Consider in Developing an Antimicrobial Stewardship 
Program To Reduce C. difficile Infection 
1. Is our organization ready for an ASP to reduce C. difficile? 
An ASP for reducing C. difficile offers a potentially promising path for facilities invested in 
and committed to the effort. Developing and implementing a successful ASP will involve 
structural, process, and cultural changes in your organization. To effect the changes needed 
in clinical practice, organizations require multiple adjustments in roles, responsibilities, 
workflow, decisionmaking, and communication. 
Failure to assess your organization’s readiness for the change at multiple levels can lead to 
unanticipated implementation challenges. Bringing about organizational change of any 
type is difficult. You will not want to move ahead until you are confident of your 
organization’s readiness. Even then, it will be important to balance the need to proceed 
thoughtfully with the need to move quickly enough to show progress and maintain 
momentum.  
Consider the following questions as you evaluate your organization’s readiness and identify 
action steps to prepare.  
1.1. Do we have the appropriate ASP foundation on which to build? 
This toolkit assumes that your hospital already has an ASP or the foundation for an ASP 
from which to launch the ASP targeted to promote appropriate antibiotic use and potential 
C. difficile reduction. Implementing and maintaining an effective ASP requires a dedicated 
multidisciplinary team and ongoing communication and collaboration as well as ongoing 
monitoring of systems. Further, ongoing monitoring may necessitate adjustments and 
corrections as you move forward.  
Before going further, you should review your facility’s current ASP or, if necessary, take 
steps to develop a basic ASP from which to target C. difficile reduction. To develop an ASP, 
you can use the GNYHA ASP toolkit. Also remember that antimicrobial stewardship is 
intended to complement other antibiotic prescribing practices and efforts to promote C. 
difficile prevention practices in your organization. You may also want to review the other 
prevention measures you have in place. 
Is there an active ASP in place? Who are its members and how does it operate? 
While team membership will vary among organizations, the traditional core ASP team 
should include an infectious disease physician and a PharmD with infectious disease 
training or experience. The clinical microbiologist, infection preventionist, hospital 
epidemiologist, information technology (IT) representative, and senior administrator will 
act as liaisons to support and supplement the core ASP team members. Ideally, the team 
should be supported by an in-house lab and IT resources.  
A newer policy statement from the Society for Healthcare Epidemiology of America (SHEA) 
suggests expanding the team and allowing members without formal infectious disease 
training to be part of the ASP team. They can facilitate implementation of ASPs and related 
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activities at more health care facilities, including those that may have fewer resources. 
Resource 1A is the Policy Statement on Antimicrobial Stewardship by SHEA, the Infectious 
Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society. 
Resources 1B, 1C, and 1D provide background information on ASPs that can serve as 
reference points for reviewing your current program’s team members and activities. 1B is 
the GNYHA/UHF Antimicrobial Stewardship Toolkit. 1C is the IDSA and SHEA Guidelines 
for Developing an Institutional Program To Enhance Antimicrobial Stewardship. 1D 
contains examples of State and local stewardship programs. 
Tool 1E can help you assess your current ASP staff resources and practices to determine 
whether you will need to strengthen the program to most effectively target C. difficile. 
What other C. DIFFICILE prevention practices are in place? 
A range of infection prevention and control practices have been effective in preventing C. 
difficile. Tool 1F highlights some of the common practices (and provides a reference for C. 
difficile clinical practice guidelines). You will need to consider how ASP can complement 
those efforts, or you may decide to strengthen some practices in conjunction with new 
antimicrobial targeting strategies. 
Resources and Tools 
Ø 1A RESOURCE: SHEA/IDSA/PIDS Policy Statement. Policy Statement on Antimicrobial Stewardship 
by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of 
America (IDSA), and the Pediatric Infectious Diseases Society (PIDS) 
Ø 1B RESOURCE: GNYHA/UHF Antimicrobial Stewardship Toolkit 
Ø 1C RESOURCE: Infectious Diseases Society of America and the Society for Healthcare Epidemiology 
of America Guidelines for Developing an Institutional Program To Enhance Antimicrobial Stewardship  
Ø 1D RESOURCE: Examples of State and Local Stewardship Programs  
Ø 1E TOOL: Assessment of Current ASP Elements 
Ø 1F TOOL: Common Evidence-Based Infection Prevention Measures 
1.2. What do we need to do before we begin to use our ASP to target C. difficile? 
Even if you have a strong stewardship foundation in place, you will need to assess your 
facility’s stage of readiness for targeting an ASP to C. difficile reduction. Developing an ASP 
to work toward reducing C. difficile will require a coordinated systems approach with 
readiness to change on many levels. Staff support and timing are important elements of 
assessing your facility’s readiness.  
You will need to begin the process of further developing your facility’s ASP by addressing 
six questions about timing, readiness, and support from various components of your 
organization. You will need to cycle back to the last five questions throughout your change 
process. Reviewing these questions will reinforce communication with colleagues and 
stakeholders and strengthen answers about the clinical case, business case, and resources 
needed as you gather data and experience.  
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Do multiple disciplines understand why a structured ASP is needed? Is there an urgency 
to change?  
Changing clinical practices and the organizational structures and processes to support new 
practices is difficult. There must be a strong motivation to change in order to successfully 
introduce new practices. You will need to identify a current and compelling reason that 
makes now the opportune time to undertake this initiative. Has some recent event brought 
attention to the problem of C. difficile rates and precipitated the desire to change?  
Participating Facility Reflections 
 A poor patient outcome, unrelated to C. difficile, prompted the facility to examine what was discovered to 
be a hospitalwide shift in susceptibilities. This discovery resulted in the development of new guidelines 
that, once instituted, resulted in a decrease in C. difficile. 
There are many potential reasons to implement an ASP to bring about a reduction in C. 
difficile. Relevant statistics, potential negative patient outcomes, and financial 
considerations all offer support for establishing an ASP. But local reasons or cases may 
prompt a more tangible and immediate increase in awareness, with a concurrent desire to 
move to implement an ASP to reduce C. difficile. For example:  
 Your facility experienced a significant increase or spike in C. difficile rates.  
 New mandated reporting requirements bring additional external scrutiny to C. difficile 
rates. 
 Your facility is responding to changes in insurance reimbursement policies. 
 Your facility had a notable adverse event that was C. difficile related.  
 Your facility has been the target of a legal action related to C. difficile. 
 Your staff has personal experience of a family member affected by C. difficile. 
While the motivation to change may be helped along by external factors, such as Federal 
mandates, it is most likely to be strong and persistent if all levels of the organization 
understand the concerns behind the planned change. 
Do senior leaders and other key stakeholders support and provide guidance to planning 
and implementing an ASP?  
While individuals who initiate the effort to reduce C. difficile through antimicrobial 
stewardship may have a clear understanding of the needed changes and the reasons for 
them, others may not. The level of knowledge and motivation in this area may vary greatly 
across the organization. Others in your hospital may have different reasons or may not 
understand the need to change, so it is important to define the issues and state the reasons 
that now is the time to institute this change. Laying the groundwork in this manner will 
help support a C. difficile reduction initiative through ASP.  
It is crucial to ensure that your organization’s leadership team and key stakeholders share 
the urgency to support development of an ASP to reduce C. difficile and are willing and able 
to provide support for this change effort. Lessons learned from other antimicrobial 
stewardship initiatives provide evidence that support is needed from both the top-level 
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administration and those at the bedside. Tool 1G provides a checklist that can help you 
assess the level of leadership support you have for an ASP to reduce C. difficile. 
If senior leaders do not already support the effort to reduce C. difficile through 
strengthening ASP, you will need to build the case for change by framing the issues and 
your plans most effectively to gain their attention:  
 For some leaders, such as your chief financial officer, it may be a business case: How 
much does C. difficile cost the hospital each year in terms, for example, of longer lengths 
of stay, additional staff time, increased readmissions, and actual medication costs?  
 For senior clinical leaders, such as the clinical chiefs and nurse executive, it may be a 
clinical case around increased morbidity and mortality associated with C. difficile.  
 For your chief executive officer, you need to consider how support for this effort fits 
with institutional values, current initiatives, and other commitments. 
In making your case, you will need to assess the leaders’ level of support and their 
understanding of the need for ongoing practical support in further developing your ASP. 
Support will involve allocation of needed resources and ongoing senior leadership 
oversight to ensure focus and accountability for results. 
Do key stakeholders in multiple disciplines understand why a structured ASP is needed?  
Your senior leadership must understand the need for both structure and staff designated to 
conducting and enhancing ASP activities. Beyond your senior leaders, you will need to 
identify key individuals of importance to this initiative by conducting a stakeholder 
analysis. Tool 1H can help you structure the stakeholder analysis to identify which 
departments and individuals are needed, what their views are about expanding the ASP, 
where barriers might exist, and what actions will be needed to obtain the necessary buy-in 
of departments and individuals. 
In addition to the stakeholder analysis, you may want to survey the prescribers in your 
organization about their views on an ASP. Understanding current attitudes will help you 
determine where education is needed and where resistance may be encountered. Lack of 
knowledge or negative attitudes may undermine change efforts if left unaddressed.  
Tool 1I is a survey instrument that was used in the ERASE C. difficile Project to assess 
physician and pharmacist perceptions about antimicrobial resistance. The survey includes 
the scope of the problem, antibiotic prescribing practices, and thoughts about ASP prior to 
the intervention.  
While prescribers are the key target group in ASPs, C. difficile reduction is a 
multidisciplinary responsibility. Engaging other clinical staff in supporting ASP and 
coordinating it with other C. difficile control practices will be critical. Therefore, you may 
want to also assess their knowledge of C. difficile control best practices and their receptivity 
to ASP. Tool 1I or another established survey tool may help you in that assessment. 
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Participating Facility Reflections 
Facilities talked about: 
 The importance of empowering all staff to feel comfortable in speaking up if, for example, infection 
control procedures were not being carried out. 
 The difficulty committing to additional activities without getting additional staff, reassigning 
responsibilities, or creatively deciding how to engage and bring on board those who have not 
previously been involved in the ASP effort. 
 The potential for nursing involvement through education and involvement in compliance with infection 
control procedures. 
 The enormous and absolutely interdisciplinary effort that starting an ASP was at their facility. 
 The crucial relationship between Infectious Disease and Pharmacy. 
 The resistance among nurses to change to piperacillin/tazobactam extended infusion because the 
additional nursing time required to set up pumps and the extra time the pump was in use with each 
patient made this intervention unmanageable. 
Is there a clinical and business case for creating an ASP for reducing C. difficile? Do 
leadership and prescribers understand and support it? 
You may decide that the most efficient and effective way to justify your wish to further 
develop your facility’s ASP is by developing and presenting a business case to your senior 
leadership. In some organizations a business case may be required. In brief, this document 
will succinctly describe the project and its aims, the risks associated with your plan, the 
expected outcomes, and the benefits and cost estimates. Resource 1J, Antimicrobial 
Stewardship: Implementation Tools & Resources: Other Resources, includes a link to two 
sample program proposals in the Business Case section that you may find helpful. 
While the goal of an ASP is to improve patient outcomes, potentially substantial financial 
benefits may be realized in cost savings. A well-conceived and presented business case that 
demonstrates to your facility administrators that the resources invested in implementing 
an ASP will be offset by benefits to the organization may help justify ongoing support. 
These benefits should be noted both in your original plan for establishing an ASP for C. 
difficile reduction and in the ASP’s results after implementation.  
Part of justifying certain ASP costs may require identification of areas where cost savings 
can be realized. Tool 1K provides a worksheet for developing a business case. Factors that 
you should consider in developing a business case include: 
 Calculating anticipated savings. You may decide to generate anticipated savings data by 
calculating costs based on current standard of care practices and comparing these costs 
with estimated costs of proposed ASP activities. In many cases if an ASP already exists, 
there will probably not be many additional costs for new staff or equipment. Rather, 
existing staff time and resources will be redirected to highlight the topic of C. difficile in 
daily ASP activities.  
 Calculating actual savings. You may decide to calculate actual costs for treating patients 
(on individual, unit, or hospitalwide basis) before introduction of ASP activities and 
after to show actual savings. You can perform this calculation using pilot data for a 
briefer timeframe or smaller scale to demonstrate savings. These pilot data can then be 
used to estimate savings if the ASP is implemented on a larger scale. 
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 Translating ASP activities into cost savings. These calculations will be based on the 
particular interventions at your facility, such as a shift from an expensive IV 
antimicrobial agent to an oral equivalent (which is likely less expensive) or a more 
narrow oral agent, discontinuation of the antibiotic completely, or shortening of the 
treatment course. Each of these scenarios has potential savings from the drug cost and 
administration costs, as well as potential savings from earlier discharge of the patient. 
In addition to the savings realized through the specific ASP activities at your facility, 
other costs should be accounted for (e.g., certain agents require more frequent 
laboratory monitoring, adding to the cost of using that particular agent). Finally, your 
facility may find that through smart antibiotic prescribing practices, your facility as a 
whole is spending less on antibiotic agents, realizing hospitalwide savings. 
 Showing that improved patient outcomes bring about cost savings. Your facility may 
choose to estimate cost savings realized through improved patient outcomes associated 
with ASP activities. Such outcomes may include reduced rates of C. difficile (because of 
strict adherence to all infection control and environmental cleaning, along with the 
specific stewardship activities); shorter lengths of stay; reduction in toxicity through 
dose optimization of targeted agents; and reduction in rates of antibiotic resistance. It 
might be important not to overstate the potential from the hospital-perspective of 
savings associated with these types of outcomes, as they may: (1) be hard to achieve, 
(2) take time to see, and (3) in some instances yield mixed financial outcomes for the 
facility (e.g., when looking purely at the business case, shortened length of stay may or 
may not actually save the hospital money). 
What kinds of resources are needed to develop an effective ASP? 
While you may not know at the outset all the kinds of support that will be needed, it is clear 
that the changes are going to require new or reallocated resources, most likely both human 
and material.  
A critical question, of course, will be who will be responsible for growing the ASP? Beginning 
with the current ASP team, factoring in the results of the stakeholder analysis conducted 
with Tool 1H, and including your plans for new ASP strategies, are additional staff 
members needed? Do the resources exist to augment current staffing?  
Less immediately obvious, but equally important, what other resources might be needed? 
These may include, for example, training, education, actual supplies/equipment/technical 
equipment and support. Tool 1L provides a worksheet for assessing these other resource 
needs. 
Participating Facility Reflections 
Both intervention and nonintervention sites shared their creative solutions and the downsides of those to 
cope with not having staff dedicated to the work of ASP, such as:  
 Use pharmacy residents who rotate through in short time periods. 
 Use infection disease fellows who assume a large portion of the workload associated with select 
interventions.  
 Use ASP team (infectious disease physician and PharmD) to supervise residents and fellows. 
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What barriers might we face and how might we deal with them? 
No new practice or innovation is seamlessly implemented without any difficulties. For 
example, in the current fiscally tight climate, your facility may be considering a number of 
programmatic options, all of which are competing for the same limited resources. You will 
need to think through the barriers you are likely to encounter so that you can anticipate 
and address them to prevent them from delaying or stopping the ASP. To stimulate your 
thinking, Tool 1M describes potential barriers to implementing an ASP, drawn from the 
hospitals participating in the ERASE C. difficile Project, and offers strategies needed to 
address them if an ASP is to be implemented. 
Participating Sites’ Reflections 
 Attempting to institute oversight of the prescribing practices of private physicians is likely to be 
politically complex.  
 Physicians may resist taking direction from pharmacists, even those trained in Infectious Diseases. 
 It will be important to create educational opportunities to help staff across disciplines understand their 
role and the interconnectedness of the various jobs in making ASP 
 
Resources and Tools 
Ø 1G TOOL: Assessing Leadership Support  
Ø 1H TOOL: Stakeholder Analysis 
Ø 1I TOOL: Survey of Staff Attitudes Toward ASP and Current Practices 
Ø 1J RESOURCE: Antimicrobial Stewardship: Implementation Tools & Resources: Other Resources  
Ø 1K TOOL: Developing Business Case  
Ø 1L TOOL: Assessing Resource Needs 
Ø 1M TOOL: Potential Barriers to Implementing an ASP 
2. How do we determine which interventions for reducing C. difficile to 
implement?  
This toolkit describes an individualized approach and tailoring of selected stewardship 
interventions based on the results of limited case-control studies and identified issues at 
each facility. As you begin to identify antibiotics to target, you will also need to look at 
prescribing practices that will be targeted for change. You will need to plan the strategies 
you will use with prescribers to appropriately limit the targeted antibiotics in use. The 
strategy will depend on a combination of known evidence-based promising practices and 
what will work in your organization. To address these issues, you should consider the four 
questions discussed in the following sections. 
2.1. What is the institutional risk assessment approach? How can it help us?  
A targeted risk assessment offers a promising path for identifying antimicrobial 
stewardship interventions to reduce C. difficile, for reasons that include the following: 
 Most ASPs have limited resources, time, and staff to have activities that affect all 
antimicrobial prescribing within their health care facility.  
 Some traditional components of a stewardship program may have little impact on C. 
difficile rates.  
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 While there may be less variability in practices for infection control and environmental 
cleaning so that bundled approaches have controlled outbreaks and prevented 
healthcare-associated infections, the same is unlikely to be true of antimicrobial 
prescribing. Prescribing can vary widely among facilities due to factors such as patient 
populations, antibiotic formularies, prescriber preference, and local microbiology. 
 Antibiotic type and use vary considerably at health care facilities throughout an area 
(formularies are large).  
The institutional risk assessment approach offers a more sophisticated approach than a 
uniform bundle of interventions at each facility. The tools below provide a roadmap for 
performing an assessment and information for tallying antimicrobial use in your facility. 
The major components of conducting an institutional risk assessment at your facility 
follow:  
 Conduct a limited case-control study to identify antimicrobial risk factors for C. 
difficile. Specifically, which of the large and diverse array of antibiotics is associated 
with C. difficile at your facility and potentially among facilities in multicampus 
institutions? Review the magnitude of the odds ratio (OR; strength of association) and 
overall use (to address attributable risk, or probability of contracting a disease; e.g., one 
antibiotic or class may have a lower OR but be used in large volume).  
 Identify and select targeted antibiotics for stewardship intervention based on the 
results of your case-control study.  
 Study patterns of use, including, but not limited to, the target populations and 
infections for which the antibiotics are being prescribed; who is prescribing them; and 
duration of use. Identify which strategies and how many different strategies should be 
implemented for each specific target. Your aim is to identify an approach that will 
address the majority of use of that antibiotic at your facility (i.e., aiming for 80%+ of 
use).  
 Include the following elements in the stewardship strategies and potential 
interventions, based on antibiotic target:  
o Restrictions and preauthorization of implicated antimicrobials. 
o Audits and feedback to providers of implicated antimicrobials. 
o Flow and algorithms for empiric and streamlined regimens for specific 
diagnoses/pathogens. 
o Antibiotic order form; automatic stop orders. 
o Novel approaches to use of stewardship staff or technology for stewardship (e.g., 
software, text paging, Pyxis pharmacy machines for tracking and promoting proper 
antibiotic prescribing). 
o Educational efforts for clinicians and patients upon diagnosis. 
Resource 2A, Institutional Risk Assessment Approach to Selecting Stewardship 
Interventions, provides a roadmap for this process. Resource 2B, A Comparison of 
Antibiotic Data Sources, can be used by facilities when considering sources of antibiotic 
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data, including strengths and weaknesses. Resource 2C describes methods for evaluating 
antibiotic use. 
For example, suppose an antibiotic associated with C. difficile at your facility (i.e., with a 
high OR or high attributable risk [high volume of use, but an OR that may not be as high]) is 
found to be used primarily for surgical prophylaxis. Strategies to address surgical 
prophylaxis choices or automatic stop orders may be appropriate to address this antibiotic. 
However, if the antibiotic is used for a specific syndrome or specific diagnoses, then flows 
and algorithms for empiric regimens for specific diagnoses, restrictions, or audit and 
feedback may be useful at your facility. 
 The case-control results and use patterns described above would guide your 
interventions; the literature, resources, and current activities at your facility would also 
be taken into account when the strategy is designed.  
 The approaches your facility develops must address how best to anticipate possible 
barriers and how to implement the strategy. 
 Compliance with the intervention and success (including changes in antibiotic use and 
rates of C. difficile) would be monitored to decide whether the strategy should be 
modified or additional interventions added.  
 A list of triggers for implementing an additional tier of interventions should be 
developed. 
Resources and Tools 
Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship Interventions  
Ø 2B RESOURCE: A Comparison of Antibiotic Data Sources 
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use 
2.2. How do we conduct a time-limited internal case-control study for C. difficile? 
What are some of the challenges?  
To identify antibiotics most associated with C. difficile cases that may be targets of 
stewardship interventions, an internal, time-limited, focused retrospective case-control 
study can be performed. The limited case-control study was chosen for a variety of reasons. 
C. difficile is a rare event, so each facility would need to look at a large volume of patients 
and antibiotic use to perform a cohort study. In addition, many facilities may not have the 
resources or expertise to perform complex formal studies. Thus, a “limited” case control 
focusing primarily on antibiotic exposures seemed more feasible, even for facilities with 
limited resources. 
There is no single perfect way to perform the case-control study. The best methods may 
vary by the specific characteristics of your facility, such as number of C. difficile cases, 
resources, personnel, availability of medical records and antibiotic use data, time, and 
interest. However, in selecting your method, there are common factors to consider, 
including the following:  
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 What is the timeframe? How many cases of C. difficile should we use? You can use 
C. difficile cases identified by the system already in place at your facility. From our 
experience, looking at cases during a 3- to 6-month period, at least 30 cases will 
probably be needed to show a statistically significant relationship between exposure to 
antibiotics and C. difficile. If feasible, looking at more cases or a longer time period may 
make it easier for you to find targets.  
 How should we choose the controls? A discussion of the advantages and 
disadvantages of choosing controls for case-control studies in general are beyond the 
scope of this toolkit. (See annotated bibliography for further resources.) From our 
experience, the most parsimonious method is to compare controls (patients who did 
not have C. difficile admitted to your facility during the same period as each case) to 
cases at a 2:1 ratio. However, since patients who develop C. difficile may be different 
from the hospital population in general, some additional criteria for choosing the 
controls can be considered, including matching for age, gender, diagnosis, and length of 
stay or other severity of illness markers.  
o Matching for age (within +/- 5 years), admission date (admitted at same time to 
same facility as the C. difficile case within +/- 5 days), and no documented C. difficile 
within 3 months before or after hospital stay seemed to yield similar data as 
matching for the above additional factors.  
o In addition, it may be practical for stewardship staff to identify controls by choosing 
the controls by hand from preprinted lists obtainable from hospital administrative 
sources. Resource 2D, Does Choice of Control Group Affect the Association of 
Antibiotics With C. difficile-Associated Diarrhea?, is a slide presentation that 
addresses these issues.  
 How should we choose and obtain the needed data? The goal of this focused case-
control study is to identify the antibiotics or antibiotic classes most associated with C. 
difficile (not all factors associated with C. difficile) as a way to identify which antibiotics 
to target with your interventions. Thus, from our experience, focusing on a few 
exposures (mostly antibiotic and a few demographics) is optimal. Some observations 
and suggestions about the data collection follow: 
o The antibiotic and other related data to be aggregated in this suggested case-control 
study are likely already collected on all patients routinely as part of either patient 
care or hospital safety measures.  
o The antibiotic data to collect may include: generic antibiotic name, dose, route, 
interval, and start and stop dates (which gives enough elements to be able to 
calculate the standard antibiotic metrics).  
o The same antibiotic and related fields are needed for the controls, including all 
documented antibiotic exposures in the 30 days prior to admission and throughout 
their inpatient stay. Although not always feasible, it would be ideal to collect data on 
“all” antibiotic exposures. However, some may have occurred during outpatient 
visits or at other facilities, and you may not be able to document them completely 
even if you conduct a detailed retrospective chart review. Thus, including all 
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antibiotics dispensed and documented within your facilities may be more realistic 
(and obtainable in many facilities in electronic form). 
o Collected data that allow description of cases and controls and ensure that these are 
similar populations at risk of C. difficile should also include: admission service, 
admission diagnosis, and top two discharge diagnoses (age and gender are likely to 
already be collected).  
o Retrospective antibiotic use data may be extracted from electronic patient medical 
and pharmacy records at your facility, but review of paper medical records may be 
needed.  
o Antibiotic use data can be summarized in electronic files (e.g., Microsoft Excel) to 
avoid using additional paper worksheets.  
Resource 2E, Sample Tracking and Summary Forms for Case-Control Study, can be used to 
organize your case-control comparisons and summarize results and potential antibiotic 
targets.  
Participating Facility Reflections 
 The nice thing about doing the case-control study is that everyone is interested in their own data; it 
lets people make decisions about what they want to do at their own hospital. It’s a trial run of sorts. 
 Interestingly, it was more difficult and time consuming to get the data than to actually conduct the 
case-control study, even if done by hand. 
 How do we analyze the data? What are resources for calculating odds ratios and p 
values?  
o Data on cases and controls can be entered or transferred into an Excel® spreadsheet 
and analyzed with a Chi square, Fisher’s exact, or other appropriate bivariate 
analysis. You can use SPSS, SAS, STATA, or another statistical software program if 
your facility has the specific software and capability. Although more detailed 
analysis including regression can be used for more complex case-control studies, for 
most facilities it will not be feasible or necessary.  
 
This is a limited case-control technique and only select antibiotic exposures will be 
examined. Smaller facilities or those with limited computer support can make the 
comparison using the Epi Info statistical calculator, a free download that is widely 
accessible and simple to use (available at www.cdc.gov/epiinfo/). You can also 
perform the patient tally and calculations by hand using this formula: 
Odds ratio (OR) = [a/b]/[c/d] or OR= [a x d]/[b x c]). 
 Exposure to Antibiotic X No exposure to Antibiotic X 
C. difficile a b 
No C. difficile c d 
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Resources and Tools 
Ø 2D RESOURCE: Does Choice of Control Group Affect the Association of Antibiotics With Clostridium 
difficile-Associated Diarrhea? 
Ø 2E RESOURCE: Sample Tracking and Summary Forms for Case-Control Study (can be used to 
organize your case-control comparisons and summarize results and potential antibiotic targets)  
2.3. What methods can we use to review the use of potential target antibiotics for 
intervention activities?  
As shown in the Institutional Risk Assessment Roadmap in Resource 2A, multiple 
approaches can be taken to reviewing the use of potential target antibiotics. You will need 
to choose the approach that best fits your organization. For example, you can conduct a 
formal medication review for several weeks or longer of prescribing patterns of the 
targeted antibiotic. For many facilities, this timeframe is unrealistic; a review of only a few 
days of prescribing patterns (potentially on random days) may suffice to begin to strategize 
interventions.  
Details to review will include but are not limited to:  
 Number of patients given prescriptions/length of therapy. 
 Most common prescribers. 
 Most common wards or patients receiving target. 
 Reason for target drug prescribing (e.g., empiric therapy, directed therapy, prophylactic 
regimen). 
 Most common syndromes and diagnoses treated by the target drug.  
 Appropriateness and potential for prescribing changes (choice, length, other options, 
including not treating if not indicated).  
Participating Facility Reflections 
 Narrowing the focus from several to just one antibiotic target can allow an increase in the number of 
interventions used and a higher number of interventions accepted. 
 Case-control study helped confirm overuse of a particular class of antibiotics (quinolones) and the 
results gave the impetus to get the usage under control. 
 Therapeutic mismatches provide opportunities for changing to an agent that will adequately cover the 
infection. 
 One tool is simply looking at the antibiogram, which almost all institutions already have on hand. One 
can then ask if the targeted antibiotic is really adding anything to empiric therapy and what are the 
alternatives. 
 It is important to discuss alternative antibiotic regimens or at least examples of how alternatives could 
be used in lieu of the target. 
 An example from our UTI guidelines was the discovery that both quinolone and 
sulfamethoxazole/trimethoprim sensitivities for E. coli were very poor on the antibiogram. Because of 
that observation, a urine pathogen-specific antibiogram (able to do rapidly with electronics) was run, 
demonstrating that sensitivities to nitrofurantoin and cephalosporins were still good and use of those 
was encouraged in the guidelines. The guidelines also call for a periodic review because sensitivities 




Resources and Tools 
Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship Interventions 
2.4. What factors do we need to consider in choosing interventions?  
The target antibiotic from the case-control study and the medication review will start to 
guide your intervention decisions. Resource 2F lists the major intervention types and their 
respective advantages and disadvantages, and Resource 2G reviews types of antimicrobial 
stewardship interventions, comparing process measures, antibiotic metrics, and other 
factors to track. These comparisons may help you determine what might be appropriate for 
your hospital. Other factors will also need to be considered, including:  
 Stewardship staffing and skill set;  
 Ability to affect a large enough burden of prescribing, IT, and other external resources;  
 Acceptability of activities to prescribers, stewardship team, pharmacy, administration, 
and other key players at your facility;  
 Previous and current stewardship activities (what has and has not worked in the past; 
what will complement current activities); and 
 Literature and best practices.  
Examples of intervention strategies from other hospitals as listed in Resource 2H may 
help you identify the interventions most likely to fit your organization. 
Participating Facility Reflections 
 Without staff dedicated to ASP, creatively using available resources is crucial; using CPOE 
[computerized physician order entry] to enhance current ASP activities by making them more 
automated, e.g., issuing alerts. 
 It’s important to strike the balance between targeting too many antibiotics and having efforts spread 
too thin, and targeting too few and not having enough opportunities to intervene. 
 The challenges of implementing an ASP in an academic setting are enormous. 
 Training is another challenge; taking away the antibiotic approvals from the fellows and assigning to 
dedicated ASP staff is dramatic as that was long considered a cornerstone in the training process. 
 Preemptive measures such as requiring prior approval were probably one of the single most effective 
means of control at my facility. 
 
Resources and Tools 
Ø 2F RESOURCE: A Comparison of Potential Antimicrobial Stewardship Interventions 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With Suggested 
Process/Monitoring, Antibiotic Use, and Additional Measures of Impact  
Ø 2H RESOURCE: Specific Intervention Examples From ERASE C. difficile Project 
2.5. How do we implement the intervention?  
Once you determine what the interventions will be in terms of the factors described above, 
you need to develop strategies tailored to your organization for implementing the 
interventions. With leadership support, the C. difficile ASP team will need to guide, 
coordinate, and support the implementation efforts during the initial phases and as the ASP 
practices are rolled out across the hospital to intended populations and prescribers.  
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Because the interventions may involve changes in the way people work, you may have 
difficulty incorporating them into practice. Our experience has been that many of these 
efforts can take longer to implement and have the full effect than initially anticipated. 
Consider the following questions to determine the changes that will be needed: 
 Whose help is needed to implement and sustain the interventions?  
o Staff within your facility. A formal review of your intended stewardship activities 
(especially if these include formulary changes, restrictions, or new policies) may be 
needed with facility staff, including the antibiotic subcommittee and pharmacy and 
therapeutics committee, infectious diseases department (including practicing 
private infectious disease doctors), and pharmacy staff. 
o Senior leadership. Buy-in and ongoing support are needed from your senior leaders. 
o Other departments. Interdepartmental cooperation and other supportive liaisons 
may be needed. Based on your intervention, you may need support and resources 
from other departments, such as pharmacy, other practicing infectious disease 
physicians, IT, microbiology, and infection preventionists.  
Participating Facility Reflections 
 Complimentary partnership of infectious disease doctors with specialty trained infectious disease 
PharmDs is effective in working with prescribers; PharmDs have expertise in dosing and infectious 
disease doctors can talk with prescribers as a peer. 
 All restriction changes have to be approved by the pharmacy and therapeutics committee; changes to 
CPOE screens have to be approved by a committee that oversees our clinical information systems; 
and information technology needs to be involved in the design, implementation, and auditing of the 
changes. 
 Do we need to pilot test the new practices? 
o Piloting may give your stewardship team a chance to work out the logistics of the 
activity, identify unexpected barriers, and develop best practices for monitoring and 
tracking outcomes. 
o Piloting will allow you to obtain some early data to determine feasibility to continue 
activities or gain additional support from administration and other stakeholders in 
your facility. 
o Piloting may help you identify other areas for stewardship activities or 
opportunities to implement an intervention. 
Participating Facility Reflections 
 Piperacillin/tazobactam audit and feedback with an educational component was piloted with infectious 




 How do we engage staff in an ASP to reduce C. difficile? How should we work with 
staff at the unit level? How can we help staff learn new practices?  
o Survey prescribers on their perceptions about issues related to C. difficile, 
prescribing practices, willingness to comply with stewardship activities, and 
concerns. This may help you understand some of the barriers you may face in 
implementation. Tool 1I, Survey of Staff Attitudes Toward ASP and Current 
Practices, is one of many similar surveys that will help you understand at baseline 
your prescriber perceptions. This tool can be administered over time to measure 
changes in perceptions. 
o Plan educational and communication activities to complement your stewardship 
interventions. This may include efforts to disseminate baseline data on C. difficile 
and prescribing concerns, along with new policies and prescribing aids (e.g., one-on-
one education, lectures, clinical information systems, and hospital intranet pages).  
o Identify “physician and prescribing champions” who will help educate and 
disseminate information and act as model prescribers from whom others can learn 
and emulate best practices. These may include hospitalists, chief residents, 
infectious disease physicians, supervising physician assistants, and other staff. In 
some facilities, attending physicians and physician assistants are often comfortable 
prescribing only a few different antibiotics and use them for many indications. 
Enlisting these different types of prescribing champions may help others in their 
prescribing. 
Participating Facility Reflections 
 Through in-house educational efforts, staff’s misconceptions that patients were coming into their 
hospital with C. difficile when, in fact, the patients were acquiring it in-house were corrected. 
3. How do we monitor the intervention and measure outcomes?  
At all points in this process you will need to monitor appropriate processes and outcomes 
of the stewardship efforts. The frequency that data are collected, compiled, and analyzed 
will vary by facility. Perhaps your facility has internal committees or boards who require 
regular submission of data; perhaps your State has a reporting requirement (e.g., C. difficile 
is reportable in New York State).  
It will be important to know the requirements at your facility so that you can make the 
proper preparations in terms of reporting mechanisms. In deciding how to monitor your 
intervention and outcomes, you should consider six questions. Some of the tools and 
resources from earlier sections will help you in this process. 
3.1. How do we measure rates of C. difficile over time? 
Many facilities are already tracking patient cases and rates of C. difficile. If your facility (or 
State/local health department) does not have a formal system, it will be easier to use or 
adapt from CDC’s NHSN system rather than creating your own definitions and surveillance. 
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Participating Facility Reflections 
Activities suggested by facilities to enhance, monitor, and sustain implementation, including C. difficile 
rates and prescribing: 
 Doing spot checks on prescribing. 
 Reviewing at regular intervals select tracking sheets/databases on prescribing. 
 Updating and initiating discussion of barriers to the antibiotic subcommittee/pharmacy and 
therapeutics committee. 
 Holding meetings with groups of prescribers from areas affected by ASP and inquiring about the 
acceptability of prescribing changes. 
 Doing spot checks of microbiology and NHSN for volume of C. difficile cases. 
 Reviewing newer/ongoing cases of C. difficile and assessing antibiotic prescribing (including whether 
there was a missed opportunity to decrease exposure). 
The following are questions to consider: 
 Whom might we need help from? You will need assistance from your microbiology 
laboratory and infection preventionists.  
 What is key information we need to be aware of? You must be aware of the methods 
of C. difficile testing and data collection in your facility. Optimally, your testing 
methodology and data collection should remain constant throughout the period of your 
intervention. While it is possible to change to a different type of testing, including more 
sensitive PCR methods, that will make meaningful comparison before and after your 
intervention activities more difficult. Also, it is important to know if there are any other 
changes that may influence C. difficile rates, such as any changes in environmental 
cleaning or infection control policies and procedures. 
 How should we track C. difficile cases? Calculating C. difficile cases per 10,000 patient 
days will allow comparison both within your facility over time and against national 
benchmarks. Tracking can be done monthly (or at longer intervals if not feasible) and 
compared quarterly. 
 Is it important to know whether C. difficile cases are acquired in our facility or in 
the community? NHSN has definitions to assess whether cases are likely acquired in 
the community or in facilities (see Web page definitions). Because many ASPs and 
targeted interventions are likely to have effects mainly in the inpatient setting, you may 
want to compare C. difficile rates for facility-onset cases (as defined by NHSN) before 
and after your intervention, rather than looking at all C. difficile cases.  
 Are we mandated to report C. difficile? Currently, public health laws in New York 
State (Public Health Law 2819) require hospitals to report several healthcare-
associated infections, including C. difficile. New York State uses the NHSN MDRO/C. 
difficile module that includes use of NHSN platform, definitions, and formatting for 
submitting required data, as shown in Resource 3A. 
 As of May 2012, five States in addition to New York (CA, IL, OR, TN, UT) mandate public 
reporting of facilitywide laboratory-identified (LabID) C. difficile events. As a result of 
the Centers for Medicare & Medicaid (CMS) Inpatient Prospective Payment System rule, 
starting in 2013, all hospitals will be required to report facilitywide LabID C. difficile 
events using NHSN. There has also been discussion that in the near future CMS is 
looking at the wider issue of requiring facilities to have a more formal stewardship 
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activities/program (see Resource 1A, Policy Statement on Antimicrobial Stewardship 
by the Society for Healthcare Epidemiology of America, the Infectious Diseases Society 
of America, and the Pediatric Infectious Diseases Society).  
 Are there Web resources to help with C. difficile surveillance? The following 
resources may be useful to your facility. 
Resources and Tools 
Ø 3A RESOURCE: Hospital-Acquired Infection (HAI) Rates in New York State Hospitals 
Ø 3B RESOURCE: About NHSN 
Ø 3C RESOURCE: NHSN Manuals and Protocols 
Ø 3D RESOURCE: NHSN Patient Safety Component, MDRO/CDI Module (customizable reporting forms, 
including Laboratory-Identified MDRO or CDI Event) 
Ø 3E RESOURCE: Instructions for Completion of the Laboratory-Identified MDRO or CDI Event Form 
3.2. How do we obtain, measure and analyze antibiotic data?  
One of the biggest challenges in antimicrobial stewardship in general and specifically in 
measuring the potential effect of an intervention is obtaining needed data on antibiotic 
volume for more than one patient at a time. Once the data are obtained, challenges arise in 
cleaning, aggregating, summarizing, and comparing the data in a meaningful way. It is 
beyond the scope of this toolkit to address every potential issue, but the following 
questions may be helpful in guiding your process:  
 What are possible antibiotic data sources? The strengths and weaknesses of the four 
main types of antibiotic data (purchasing, orders, antibiotics dispensed, and antibiotic 
receipt) are summarized in Resource 2B, A Comparison of Antibiotic Data Sources. If 
your facility is just starting ASP efforts or has little IT support, purchasing can be both a 
feasible way to start to identify problem drugs and a quick way to show the effects of 
early intervention measures. 
 What are some common antibiotic data cleaning and aggregation challenges? 
Getting the right data from even the most sophisticated hospital or pharmacy clinical 
information system is often an iterative process. Even with good IT support, data may 
be given to you that are not ready for immediate analysis. We recommend some 
validation to ensure that the data make sense. Reviews of purchasing data or focused 
chart reviews are two means to reality check the larger volume of use data. Check the 
data to verify that all drugs are included. Many facilities use generic drugs; with drug 
shortages, products may vary throughout the year; and some drugs will need to be 
removed as they are no longer used for their antimicrobial properties. In multifacility 
medical centers, it is important to standardize drugs and dosing to aggregate and 
compare over campuses. 
 What are some antibiotic metrics we can consider using? Resource 2C, Possible 
Methods for Evaluating Antibiotic Use, describes methods for summarizing and 
comparing antibiotic use. It includes definitions, strength, considerations regarding use, 
and references to learn more about each measure. Resource 2G, A Review of 
Antimicrobial Stewardship Interventions With Suggested Process/Monitoring, 
Antibiotic Use, and Additional Measures of Impact, links some of the common 
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intervention activities and suggested potential antibiotic metrics to access and compare 
prior to, during, and after the interventions.  
o You will likely need IT support to obtain aggregate data. Often if antibiotic receipt 
data are obtained, the database can be large and difficult to manage. It also may 
require cleaning and combining data substantially before any metrics or 
comparisons can be used.  
o Often using more than one metric will give you a more complete picture of the 
baseline and postintervention use. 
o Depending on the extent and nature of the intervention activities, it may take time 
for you to see changes in antibiotic use, depending on the metric chosen for that 
particular intervention. For example, restrictions likely see effects sooner, while 
audit and feedback activities or new algorithms may take longer to take hold and 
change prescribing. Some interventions may be in specific units or populations, so a 
hospitalwide metric may not be refined enough to show differences. 
Participating Facility Reflections 
 Piperacillin/tazobactam turned out to be a very challenging target; the strategies initially identified—
de-escalation and duration—did not make a very big dent. 
 Implementing an intervention in one unit may make it difficult to see results if antibiotic data and C. 
difficile rates are calculated on a hospitalwide basis. 
 
Resources and Tools 
Ø 2B RESOURCE: A Comparison of Antibiotic Data Sources 
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With Suggested 
Process/Monitoring, Antibiotic Use, and Additional Measures of Impact  
Ø 3F RESOURCE: World Health Organization Defined Daily Dose Definition and General Considerations 
(links on left side of page go to DDD lists)  
3.3. How can we monitor the intervention and why should we? 
It is important to monitor the interventions for multiple reasons. You will need to: 
 Be able to verify that the interventions are occurring. 
 Look for early and tangible signs of success (antibiotic metrics may be slow to show 
effects).  
 Identify barriers to success and ways to improve the intervention. 
 Assess whether additional interventions are needed. 
 Determine whether the interventions are sustainable. 
 Learn whether the intervention could be an effective way to affect other outcomes, such 
as C. difficile and antibiotic resistance.  
This last point is important because many stewardship interventions have been successful 
in reducing targeted antibiotic use and cost but have fallen short in reducing more concrete 
outcomes such as C. difficile rates and antibiotic resistance. If these outcomes are not 
achieved, monitoring the intervention is important to distinguish why the intervention did 
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not demonstrate an impact. Was it because the activities were not completed; the 
intervention could not affect prescribing practices, antibiotic use, or outcomes; the 
activities were not implemented long enough to see impact; transmission was a bigger 
problem than anticipated; or  the mechanism of resistance presented problems? Resource 
2G, A Review of Antimicrobial Stewardship Interventions, summarizes some suggested 
monitoring or process measures for specific antibiotic stewardship intervention activities. 
Participating Facility Reflections 
 The lowest rates of intervention ―acceptance‖ are in July-September, which coincides with the new 
group of pharmacy residents who are tentative in their recommendations and whose 
recommendations are less likely to be accepted. This is known because of ongoing monitoring. 
 Similar comments were made about infectious disease fellows having the knowledge, experience, 
confidence, and backing enforcing restrictions early in the academic year. 
 
Resources and Tools 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With Suggested 
Process/Monitoring, Antibiotic Use, and Additional Measures of Impact  
3.4. What other processes do we need to monitor and measure? 
It is also important to ensure that your interventions do not have unintended consequences 
for your patients. Thus, looking at rates of reinstitution of broad antibiotic therapy, missed 
or delayed antibiotic doses, or readmission (especially for infection) should be part of your 
ongoing surveillance, along with examination of mortality data. In addition, your 
interventions may have other positive outcomes (e.g., reduced length of stay for patients 
receiving the intervention) that you will need to monitor and keep track of.  
Further, your institution’s infection control, isolation precautions, and environmental 
cleaning policies and practices should be monitored throughout your intervention as 
changes in these can also affect C. difficile rates. Resources 3G and 3H offer examples of 
tools for monitoring prevention practices.  
Finally, it is important to assess how the intervention affects your stewardship team and 
other prescribers. Qualitative data collection (ideally pre- and postintervention) such as 
prescriber surveys (see Tool 1L), informal discussions, or focus groups may enrich your 
understanding of the ASP and activities at your facility. 
Resources and Tools 
Ø 1L TOOL: Survey of Staff Attitudes Toward ASP and Current Practices 
Ø 3G/3H RESOURCE: Environmental Cleaning and Infection Prevention Checklists  
3.5. How do we analyze financial data? 
It will be important to conduct a financial impact analysis at your facility to estimate the 
costs associated with running an ASP, including staffing, software, and equipment; estimate 
the cost savings from reduced antimicrobial use; and understand the potential 
reimbursement impact of reducing infections. In addition, you may want to estimate 
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indirect savings, including savings on isolation equipment or estimated savings from 
meeting external quality measures, such as those from CMS.  
You may choose to examine antibiotic purchasing data if those data are available, or you 
may need to use industry sources to estimate costs associated with antibiotic purchasing. 
Data from the hospital should be available as they are routinely compiled for internal 
hospital purposes or required external use (e.g., billing). In the current climate of 
competing demands, leadership is frequently interested in the ways patient safety 
initiatives translate into financial savings. 
3.6. How do we assess the overall impact of our interventions? How do we decide 
which interventions have been the most successful (and which interventions 
were not) and why? 
Assessing the overall impact of an intervention can be complex. Following are some 
important points gleaned from the participating facilities and interpretation of the analysis 
and evaluation components by our ERASE C. difficile leadership team.  
Simplistically showing a decrease in the targeted antibiotic consumption might 
suggest success. One issue that we encountered is that depending on the specific 
antibiotic, dosing, and type of intervention, the commonly used antibiotic metrics of 
defined daily dose, days of therapy, and number of courses may not reflect the changes in 
prescribing exactly the same way.  
In addition, a large enough proportion of the prescribing needs to be affected to be 
measurable in the aggregate antibiotic use measures or to potentially improve other 
outcomes (e.g., C. difficile infections). For example, in several of the participating facilities, 
piperacillin/tazobactam was a target. But this is a broad antibiotic an array of prescribers 
often use for empiric regimens or for various infections. Thus, an intervention that targets 
only a fraction of that prescribing may be successful in decreasing that specific indication 
for prescribing but may not be able to be measured when overall prescribing is 
summarized.  
Since C. difficile has multifactorial causes, affecting only one drug or the prescribing of only 
a proportion of the prescribing of that specific drug may not affect the rates of C. difficile. 
This is likely also true of antibiotic resistance patterns. In addition, it may take longer to 
influence C. difficile and other microbiologic targets. Thus, for interventions of short 
duration, it will be difficult to show changes and you may not be guaranteed to see changes 
in these measures even in the long run.  
Further, some interventions may shift antibiotic prescribing but not reduce use. If the 
shift is to a more narrow antibiotic, an oral antibiotic regimen, or no antibiotics, the patient 
may have positive outcomes but experience unintended consequences. For example, if an 
antibiotic is restricted and prescribers move to an alternative nonrestricted antibiotic, an 
unintended increase can occur in use of the second antibiotic. Patients may then experience 
secondary unintended consequences (e.g., have more side effects, be more difficult to 
dose). The drug also may have other effects on the local microbiologic flora, be a mismatch 
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to the patient’s culture results, and result in readmission or increased length of stay. Thus, 
a shift in prescribing can be good and bad, so reviewing the patterns of antibiotic 
prescribing in general and not just of single agents is important. 
Other potential surrogates or outcomes for review are length of stay and cost. A 
decrease in the length of treatment may allow more prompt discharge of patients, which 
should be balanced with a review of readmissions for infections. An assessment of cost to 
implement the intervention and potential cost savings from fewer or different patterns of 
antibiotic use can be useful, especially when advocating for more formal resources from 
hospital administration.  
Several other factors are important to consider when assessing the impact of an 
intervention. It is important to explore the ability to implement the intervention in 
terms of cost, staffing, IT support, and timeframe. You also need to assess the 
acceptability to the stewardship team (does not impede other needed stewardship 
activities) and to prescribers. Not all activities will be welcomed, but some may be less 
popular than others. This can make it difficult to cast the ASP team in an educational role 
with prescribers, making it more difficult to implement other needed changes.  
All these factors can also affect the ability to sustain activities. Thus, activities have to 
be considered in the setting of longer range goals for the ASP.  
Ultimately, your facility will probably weight a combination of these factors when you 
choose to implement new or supplement existing antibiotic stewardship activities. 
Interventions need to be tailored and must complement other factors in your facility’s 
environment. 
Participating Facility Reflections 
 A dramatic drop in cost has been realized; a 7-day course of antibiotics is not the norm anymore. 
 Quinolone use was reduced by 20 percent through a variety of interventions. 
 A notable dip in piperacillin/tazobactam use after systemwide restriction led to a shift from one broad 
spectrum agent to another. 
 
Resources and Tools 
Ø 2H RESOURCE: Specific Intervention Examples From ERASE C. difficile Project 
4. How do we sustain the ASP for reducing C. difficile over time?  
Early in the process of developing your ASP aimed at reducing C. difficile, you will need to 
think ahead about sustaining the program once it is in place. Often, sustaining changes in 
clinical practice introduced through a new initiative is more difficult than implementing 
them initially. To maintain your ASP for C. difficile reduction so that it thrives and continues 
to be useful, consider at least four questions; you may have others.  
In considering these questions, reflect on the challenges you currently face and consider 
strategies for working on them in the future. Tool 4A provides a worksheet for doing that. 
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The four questions are discussed below. The tools and processes introduced in earlier 
sections, such as the business plan Tool 1K, also can be used in developing your 
sustainability plan.  
Will our current ASP staffing work on an ongoing basis? 
How well is your stewardship team working across departments and disciplines? What is 
the current distribution of responsibilities? Are there changes that you would need to 
make? 
What is the plan for ongoing measurement and feedback?  
A plan is only as good as the systems in place that ensure sustainability. It is crucial to plan 
at the onset for ongoing monitoring, maintenance, and evaluation of the ASP for reducing C. 
difficile. Section 3 talked in detail about monitoring the ASP for C. difficile intervention and 
outcomes as you are planning and initially implementing the program. Measurement and 
feedback will be equally important as you transition to sustaining the program.  
What ongoing organizational support will we need to keep the new ASP practices 
in place?  
Maintaining your ASP requires organizational support on multiple levels. Ongoing 
organizational support for ASP to reduce C. difficile will be strongest if you can demonstrate 
that it is aligned with the medical center’s strategic priorities and that it addresses pressing 
problems.  
How do we keep the ASP efforts relevant and a continued focus?  
As discussed in greater detail in Section 1.2, given the environment of tightening resources 
in most medical centers, you will likely need to keep your preliminary business case 
updated and current to ensure continued or expanded investment in your ASP. 
Resources and Tools Used by Participating Facilities 
Ø 4A TOOL: How Do We Sustain ASP for Reducing C. difficile Over Time? 
Ø 4B TOOL: UTI Guidelines Form 
Ø 4C TOOL: Piperacillin/Tazobactam De-Escalation Form 
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Summary of Tools and Resources 
Section Question Addressed Resources and Tools 
1. Is our organization 
ready for an ASP to 
reduce C. difficile? 
1.1. Do we have the 
appropriate ASP 
foundation on which to 
build? 
 
Ø 1A RESOURCE: SHEA/IDSA/PIDS Policy Statement. Policy Statement on 
Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America 
(SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric 
Infectious Diseases Society (PIDS) 
Ø 1B RESOURCE: GNYHA/UHF Antimicrobial Stewardship Toolkit 
Ø 1C RESOURCE: Infectious Diseases Society of America and the Society for 
Healthcare Epidemiology of America Guidelines for Developing an Institutional 
Program To Enhance Antimicrobial Stewardship  
Ø 1D RESOURCE: Examples of State and Local Stewardship Programs  
Ø 1E TOOL: Assessment of Current ASP Elements 
Ø 1F TOOL: Common Evidence-Based Infection Prevention Measures 
 1.2. What do we need to 
do before we begin to use 
our ASP to target C. 
difficile? 
 
Ø 1G TOOL: Assessing Leadership Support  
Ø 1H TOOL: Stakeholder Analysis 
Ø 1I TOOL: Survey of Staff Attitudes Toward ASP and Current Practices 
Ø 1J RESOURCE: Antimicrobial Stewardship: Implementation Tools & Resources: 
Other Resources  
Ø 1K TOOL: Developing Business Case  
Ø 1L TOOL: Assessing Resource Needs 
Ø 1M TOOL: Potential Barriers to Implementing an ASP 
2. How do we determine 
which interventions for 
reducing C. difficile to 
implement? 
2.1. What is the 
institutional risk 
assessment approach 
and how can it help us? 
Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship 
Interventions  
Ø 2B RESOURCE: A Comparison of Antibiotic Data Sources 
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use 
 2.2. How do we conduct a 
time-limited internal case-
control study for C. 
difficile? What are some 
of the challenges?  
Ø 2D RESOURCE: Does Choice of Control Group Affect the Association of Antibiotics 
With Clostridium difficile-Associated Diarrhea? 
Ø 2E RESOURCE: Sample Tracking and Summary Forms for Case-Control Study 
(can be used to organize your case-control comparisons and summarize results and 
potential antibiotic targets) 
 2.3. What methods can 
we use to review the use 
of potential target 
antibiotics for intervention 
activities?  
Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship 
Interventions  
 2.4. What factors do we 
need to consider in 
choosing interventions?  
Ø 2F RESOURCE: A Comparison of Potential Antimicrobial Stewardship Interventions 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With 
Suggested Process/Monitoring, Antibiotic Use, and Additional Measures of Impact  




Summary of Tools and Resources 
Section Question Addressed Resources and Tools 
3. How do we monitor the 
intervention and measure 
outcomes? 
3.1. How do we measure 
rates of C. difficile over 
time? 
Ø3A RESOURCE: Hospital-Acquired Infection (HAI) Rates in New York State 
Hospitals  
Ø 3B RESOURCE: About NHSN 
Ø 3C RESOURCE: NHSN Manuals and Protocols 
Ø 3D RESOURCE: NHSN Patient Safety Component, MDRO/CDI Module 
(customizable reporting forms, including Laboratory-Identified MDRO or CDI Event)  
Ø 3E RESOURCE: Instructions for Completion of the Laboratory-Identified MDRO or 
CDI Event Form 
 3.2. How do we obtain, 
measure, and analyze 
antibiotic data?  
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With 
Suggested Process/Monitoring, Antibiotic Use, and Additional Measures of Impact 
Ø 3F RESOURCE: World Health Organization Defined Daily Dose Definition and 
General Considerations (links on left side of page go to DDD lists)  
 3.3. How can we monitor 
the intervention and why 
should we? 
Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With 
Suggested Process/Monitoring, Antibiotic Use, and Additional Measures of Impact 
 3.4. What are other 
processes we need to 
monitor and measure? 
Ø 1I TOOL: Survey of Staff Attitudes Toward ASP and Current Practices 
Ø 3G/3H RESOURCE: Environmental Cleaning and Infection Prevention Checklists 
 3.6. How do we assess 
the overall impact of our 
interventions? How do we 
decide which 
interventions have been 
the most successful (and 
which interventions were 
not) and why? 
Ø 2H RESOURCE: Specific Intervention Examples From ERASE C. difficile Project 
4. How do we sustain the 
ASP for reducing C. 
difficile over time? 
 Ø 4A TOOL: How Do We Sustain ASP for Reducing C. difficile Over Time? 
Resources Developed and 
Used by Participating 
Facilities 
 Ø 4B TOOL: UTI Guidelines Form 
Ø 4C TOOL: Piperacillin/Tazobactam De-Escalation Form 




Ø 1E TOOL: Assessment of Current Antimicrobial Stewardship Program Elements  
Purpose: To help assess which ASP elements are currently in place in terms of staff and 
strategies. 
Source: Adapted from Greater New York Health Assocation/United Hospital Fund ASP 
Chapter 2, “The Antimicrobial Stewardship Core Team,” and Chapter 3-B, “Core Strategies.”  
Instructions: Complete checklist, review responses to ascertain the level of leadership 
support, and target areas that need strengthening to move forward. 
STAFF RESOURCE Check If Available: 
Infectious disease–trained physician  
Clinical pharmacist  
Clinical microbiologist  
Infection control representative  
Hospital epidemiologist  
Information technology  
STRATEGIES IN PLACE  
Prospective audit with intervention and feedback  
Education   
Guidelines and clinical pathways   
Antimicrobial cycling   
Antimicrobial order forms   
Formulary restriction and preauthorization  
Combination therapy   
Streamlining or de-escalation of therapy   
Dose optimization   
Parenteral to oral conversion   
Health care information technology   
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Ø 1F Tool: Common Evidence-Based Infection Prevention Measures 
Purpose: To understand and assess infection control measures in use at your facility and 
give suggestions for additional measures to be taken. 
Source: Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 
Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious 
Diseases Society of America (IDSA). Available at: www.jstor.org/stable/10.1086/651706.  
Instructions: Complete checklist and review procedures currently in place for infection 
prevention. Consider additional measures that may be needed and identify areas that need 
strengthening. 
Infection Control and Prevention for C. difficile Infection: What Health Care Workers, 
Patients, and Visitors Can Do 
Precaution 
In Use: 
Y/N Corrective Measures To Be Taken 
Use of immediate contact precautions 




Hand hygiene protocol in place (soap 
and water preferred) before and after 




Personal protective equipment readily 




Policy for use of private rooms for C. 
difficile patients 
 Yes 
 No  
 
Policy for cohorting patients if private 











Ø 1G TOOL: Assessing Leadership Support 
Purpose: To assess senior administrative leadership support for improving C. difficile 
prevention and allocating needed resources for improvement activities.  
Source: Developed by ERASE C. difficile project team. 
Instructions: Complete checklist, review responses to ascertain the level of leadership 
support, and consider which areas and strategies need strengthening.  
Leadership Support Assessment Yes No Partial Comment 
C. difficile prevention beyond current 
practices is a high priority within the 
facility 
    
There are visible role models/champions 
for antimicrobial stewardship for reducing 
C. difficile 
    
The facility has implemented antimicrobial 
stewardship policies 
    
There is a dedicated budget allocated for 
infection control activities 
    
The budget includes funding for education 
and training on infection control, including 
antimicrobial targeting 
    
The budget includes funding for 
information technology to support 
infection control, including antimicrobial 
targeting 
    
33 
Ø 1H TOOL: Stakeholder Analysis 
Purpose: To help identify how specific departments and disciplines will be involved in 
planning and implementing ASP strategies and to identify actions needed to obtain buy-in 
and participation. 
Source: Adapted from Project Agency. Blank project management templates. Available at: 
http://www.businessballs.com/project%20management%20templates.pdf. 
Instructions: Interview key institutional stakeholders, and identify actions to involve them 
in the planning and eventual implementation of an ASP. Modify stakeholder list to meet the 
needs of your institution. 
Stakeholder/ 
Discipline 











be involved in 
to plan and 
implement 
ASP? 







What actions can be 
taken to strengthen 
the buy-in from this 
key stakeholder to 






    
Clinical 
pharmacist 
    












    
Prescribing 
provider 
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Ø 1I TOOL: Survey of Staff Attitudes Toward ASP and Current Practices 
Purpose: To assess prescribers’ perceptions about antimicrobial resistance, including the 
scope of the problem, antibiotic prescribing practices, and thoughts about antimicrobial 
stewardship programs. This information should inform implementation strategies and 
identify education needs. 
Source: Developed by Greater New York Health Association/United Health Fund ERASE C. 
difficile Project team. Based on the AHRQ Hospital Survey on Patient Safety Culture. 
Available at http://www.ahrq.gov/qual/patientsafetyculture/hospsurvindex.htm. 
Instructions: Have prescribers complete the survey. Consider handing it out and collecting 
it at a faculty meeting or Grand Rounds where they are already gathered. Tally results for 
use by the ASP team and clinical educators. Also consider presenting survey results to 
prescribers to provide feedback about the collective attitudes and perceptions in your 
facility.  
Note: The survey is separate from these instructions so that it may be easily duplicated for 
use. 
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ERASE- C. diff. Antimicrobial Stewardship Survey 
(This survey is designed to be administered pre- and postintervention and to both intervention 
and control institutions.) 
Please indicate your level of agreement with the following statements about your institution.  
Antimicrobial Resistance: Scope of the Problem and Key Contributors 
 Strongly 
Disagree Disagree Neither Agree 
Strongly 
Agree 
1. Antibiotic resistance is a problem in this 
institution. 
     
2. Patient rooms are cleaned according to hospital 
cleaning protocol once a C. difficile patient has 
been discharged. 
     
3. Adherence to hand hygiene protocols is 
excellent at this institution. 
     
4. Adherence to isolation and contact precautions 
is excellent at this institution. 
     
5. This institution does NOT do enough to control 
the development of C. difficile.  
     
6. This institution provides adequate staff education 
regarding C. difficile. 
     
7. A patient is likely to develop a C. difficile 
infection during a stay at this institution. 
     
Antibiotic Prescribing Practices 
 Strongly 
Disagree Disagree Neither Agree 
Strongly 
Agree 
1. Microbiology lab results are efficiently 
communicated to the treating physician. 
     
2. I regularly refer to the susceptibility/sensitivity 
patterns at this institution (e.g., an antibiogram) 
when prescribing antibiotics.  
     
3. If medically appropriate, intravenous antibiotics 
should be stepped down to an oral alternative 
after 3 days. 
     
4. Restrictions on antibiotics impair my ability to 
provide good patient care.  
     
5. Antibiotics are overused at this institution.      
6. A majority of patients admitted to this institution 
will be prescribed at least one antibiotic during 
their hospital stay. 
     
7. Many of my patients receive 5 or more days of 
antibiotics during their stay at this institution. 
     
8. Few of my patients are discharged from this 
institution on antibiotics.  
     
9. When discharged to a nursing home or long-
term care facility, most of my patients are on IV 
antibiotics.  
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Antimicrobial Stewardship Programs (a formal program that monitors and manages the appropriate use 
of antibiotics) 
 Strongly 
Disagree Disagree Neither Agree 
Strongly 
Agree 
1. Antimicrobial stewardship programs can improve 
patient care. 
     
2. Antimicrobial stewardship programs reduce the 
problem of antimicrobial resistance. 
     
3. Antimicrobial stewardship programs can affect 
this institution’s C. difficile rates.  
     
4. This institution has an effective antimicrobial 
stewardship program. 
     
5. This institution does NOT provide adequate 
training on antimicrobial prescribing and use. 
     
6. Additional staff education on antimicrobial 
prescribing is needed. 
     
7. Prescribing physicians are the only disciplines 
who need to understand antimicrobial 
stewardship. 
     
Background Information 
1. What is your primary work area or unit in this health care facility? (Please check ONE answer) 
 Many different units/No specific unit  
 Medicine (nonsurgical)  Intensive care unit (any type)  Radiology 
 Surgery  Psychiatry/mental health  Anesthesiology 
 Obstetrics  Rehabilitation  Other (please specify: 
 Pediatrics  Pharmacy                     ) 
 Emergency department  Laboratory  
2. How long have you worked in this health care facility?  
 Less than 1 year  11 to 15 years 
 1 to 5 years  16 to 20 years 
 6 to 10 years  21 years or more 
3. What is your staff position in this health care facility?  
  Attending/staff physician  Physician assistant  
  Resident physician/Intern  Nurse practitioner 
  Fellow  Infection control practitioner 
  Pharmacist  Other (please specify:                    ) 
4. How long have you worked in your current specialty or profession? 
 Less than 1 year  6 to 10 years  16 to 20 years 
 1 to 5 years  11 to 15 years  21 years or more 
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Ø 1K TOOL: Developing the Business Case 
Purpose: To make the case for ASP implementation for reducing C. difficile. Early in the 
project, the arguments will be prospective, looking at expected benefits. After your ASP for 
reducing C. difficile is implemented, you can use the same form to document realized 
benefits. 
Source: Adapted from Project Agency. Blank project management templates. Available at: 
http://www.businessballs.com/project%20management%20templates.pdf  
Instructions: Complete the form to be used in presentations and discussions with senior 




Expected Outcomes, Both Clinical and Financial 
Benefits of Project 
Initial Estimates of Cost and Time 
$: 
Time: 
Outcome of the Business Case 
Decision From (xxx) 
Date 
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Ø 1L TOOL: Assessing Resource Needs  
Purpose: To identify resources needed to initially implement and later sustain an ASP for 
reducing C. difficile. The ASP team may revise or amend assessment as implementation 
proceeds and other resources are needed.  
Source: Developed by AHRQ Pressure Ulcer Prevention Toolkit project team. 
Instructions: Complete checklist to assess resources available and resources needed.  
Resource Needs Assessment 
Needed: 
Yes/No Notes on What Is Needed 
Funds   
Other resources:   
Education department   
Printing/copying   
Graphics/design   
Facilities and supplies   
Physical therapy/occupational 






Nonclinical time for team 
meetings and activities 
  
Information Technology support   




Ø 1M RESOURCE: Potential barriers to implementing an ASP  
Purpose: In the current fiscally tight climate, your facility may be considering a number of 
programmatic options, all of which may be competing for the same limited resources. The 
following information was collected on visits to several project nonintervention sites and 
describes potential barriers to implementing an ASP, as well as what is needed to 
implement an ASP.  
Source: ERASE C. difficile Project team. 
Instructions: Review document to identify if a barrier exists and if resolution is available. 
Potential Barriers to Implementing an ASP 
Category Barrier 




 Insufficient understanding of the 
scope of the problems/lack of 
sufficient training and education 
 Potential for savings realized from 
ASP to return to hospital’s general 
operating fund rather than 
enhancing ASP services and overall 
programming  
 Expanded education and training for 
staff at all levels and in all services 
 Administrative approval to direct 
savings realized from ASP to staff 
dedicated to enhancing ASP (rather 
than these additional funds going back 
to hospital general fund)  
Resources and 
Staffing 
 Insufficient staffing (information 
technology [IT], pharmacy, infectious 
diseases [ID]); lack of dedicated staff 
and capabilities 
 Potential to compromise clinical care 
without dedicated staffing 
 Lack of ID/administrative champion 
onsite 
 Ability (via administrative support) to 
convert demonstrated savings into 
additional dedicated staff (assigned 
PharmD) 
 Outreach and training to make 
interdisciplinary cooperation seamless 
 Dedicated IT/pharmacy/ID staff 
 Ability to maintain clinical services 
without additional staff dedicated to 
ASP activities in IT, ID, and pharmacy 
Data Systems  Insufficient baseline and ongoing 
data collection or review 
 Need for system to alert ID 
pharmacists of target patients 
 Medical record system either not 
fully electronic or not fully integrated 
 Ability to formally track outcomes 
 System in place to alert ID pharmacists 
of target patients 
 Improved data collection and review 
system 
 Improved medical records system 
(conversion to electronic or fully 
integrated system) 
 Enhanced reporting capabilities of 
pharmacy 
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Potential Barriers to Implementing an ASP 
Category Barrier 




 Issue of private ID physicians doing 
hospital consults  
 Issue of house staff taking clinical 
directives from pharmacy; current 
prescribing culture 
 Issue of private ID physicians 
assisting with surveillance 
 Issue of hospitalists not taking 
responsibility for decisionmaking on 
rounding 
 Training in proper use of antibiogram 
 Training to encourage collaboration of 
infection prevention and pharmacy 
services 
 Training of hospitalists 
Institutional 
Demographics 
 Smaller facilities that lack onsite full-
time ID physicians and full-time 
dedicated staff 
 Larger facilities whose staffing to 
bed size ratios only allow limited 
review of antibiotic prescribing 
 Facilities with different economic 
constraints and many other 
competing priorities 
 Ways to tailor activities and 
interventions to your needs, size, 
resources, patient and prescriber 
populations, and staffing 
 Among smaller facilities, an option for 
stewardship activities a few times per 
week (audit and feedback with 
contracted ID staff) 
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Ø 2A RESOURCE: Institutional Risk Assessment Approach to Selecting Stewardship 
Interventions 
Purpose: A roadmap to illustrate the steps involved in developing an institutional risk 
assessment approach to antimicrobial stewardship.  
Source: Adapted from ERASE C. difficile Project tools. 





Institutional Risk Assessment  
Approach to Selecting Stewardship Interventions
Case-Control Study





Review of Aggregate 
Antibiotic Use for 








- Who is prescribing?
- For what is the 
antibiotic used?





(examples included but not limited to)
1. Are they used in clinical 
pathways? (see box B: 2, 3, 
or 6) 
2. Are they used for surgical  
prophylaxis (see box B: 4)
3. Are they used to treat 
certain syndromes or 
diagnoses? (see box B: 1, 
2, or 3)
4. Is there opportunity for 
restriction? (see box B: 1)
5. Is a formulary change 
needed? (see box B: 1)
6. Are they used for specific 
patient populations (e.g., 
febrile neutropenic patients. 
see box B: 3 and 6)
7. Are the courses 
prolonged? Is there an 
opportunity to deescalate 
or discontinue antibiotics? 
(see Box B: 2)
Choice of Intervention Type To 
Address Majority Associated 
With CDI cases (target 80% or 
better of total)
(examples included but not limited to)
1. Formulary changes, restrictions, 
and preauthorization of implicated 
antimicrobials
2. Audits and feedback to providers of 
implicated antimicrobials
3. Flow and algorithms for empiric and 
streamlined regimens for specific 
diagnoses/pathogens
4. Antibiotic order form, automatic stop 
orders
5. Novel approaches to use of 
stewardship staff or technology for 
stewardship (e.g., software, text 
paging, Pyxis pharmacy machines 
for tracking and promoting proper 
antibiotic prescribing)
6. Educational efforts for clinicians and 
patients upon diagnosis
Plan Implementation of Intervention
Measure Compliance and 
Impact on CDI Rates






Ø 2B RESOURCE: A Comparison of Antibiotic Data Sources 
Purpose: A tool to review sources of antibiotic data. 
Source: Developed by B. Ostrowsky and P. Chung, Montefiore Medical Center, for ERASE C. 
difficile Project toolkit. 
Instructions: Use this chart when considering sources of antibiotic data, including strengths 
and weaknesses. 
Source Advantages Disadvantages 
Purchasing  Easiest data to obtain 
for baseline (most 
pharmacies track, 
even if not full 
computerized 
physician order entry 
[CPOE])  
 Can be converted into 
defined daily doses to 
get estimates of use 
 Comparison possible 
before and after 
interventions  
 Simple to convey 
results to stakeholder 
 Likely aggregated facility-level data only (not patient 
level) 
 May be influenced by contract pricing 
 Can vary at different times of year (since ordering can 
be sporadic and availability of generic and other 
drugs can vary over time) 
Orders  Can be aggregated by 
patient  
 Represents only prescriber intent (orders change) 
and not necessarily what patients receive  
 Unless done by chart review, requires some 
pharmacy electronic tracking system 
Medication 
dispensed 
 Can be aggregated by 
patient 
 Represents what pharmacy dispenses and not 
necessarily what patients actually receive (medication 
may be wasted) 
 Unless done by chart review, requires some 
pharmacy electronic tracking system 
Medications 
received  
 Best data; represents 
actual medication 
receipt  
 Can be aggregated by 
patient 
 Unless done by chart review, requires CPOE or other 
advanced pharmacy electronic tracking system 
 Needs information technology to help obtain, 
organize, and aggregate data in meaningful way 
 Labor intensive to clean and aggregate (often large 
files)  
 
Ø 2C RESOURCE: Possible Methods for Evaluating Antibiotic Use 
Purpose: A tool to review types of antibiotic use metrics. 
Source: Developed by R. Ruiz, Greater New York Healthcare Association, for ERASE C. difficile Project toolkit. 
Instructions: Use when considering ways to measure antibiotic use. Includes descriptions, strengths, consideration, types of 
stewardship interventions for which metrics have monitoring potential, and resources/references.  
Metric Description Strengths Considerations 
Monitoring 
Potential References 
Defined daily dose 
(DDD)* 
Average maintenance dose 
per day for a drug used for 
its main indication in adults. 
Gives an estimate of 
antibiotic consumption. 




Standardized DDD is 
independent of price and 
dose 
 
DDDs exist for common 
combination therapies 
 
Calculated DDDs account 
for dose and frequency 
given 
DDD does not reflect the 
recommended or prescribed 
dose 
 
Most times the DDD is a 
compromise of doses used 
in different countries 
 
Standardized DDD is rarely 
the prescribed dose due to 
averaging of common doses 
used 
 
DDD can only be used for 
adults 
 
Calculation over time may be 














Days of therapy 
(DOT) 
Number of days when at 
least one dose of a 
medication was 
administered irrespective of 
dose or route of 
administration 
Allows comparison of the 
length of treatment 
 
Can be used for children 
 
Not dependent on 
standardized dose (like 
DDDs) for uncomplicated 
calculation over time 
Does not take into account 











Metric Description Strengths Considerations 
Monitoring 
Potential References 
Number of courses Number of prescribed 
courses of unique antibiotics 
per person. Courses cannot 
have more than a 48-hour 
window between any two 
consecutive administrations.   
Allows comparison of 
antibiotic prescription 
patterns 
Does not take into account 
dose or frequency  
 
Does not take into account 










≥Three antibiotics  Number of patients on three 
or more antibiotics 
Can be used to identify 
patients with more severe 
acuity and possibly at 
higher risk for 
complications (e.g., C. 
difficile) 
Does not take into account 
dose or frequency 
 
Does not take into account 
specific combinations of 
antibiotics 
 
May be prone to a small 





a. World Health Organization Collaborating Centre for Drug Statistics Methodology. International language for drug utilization research. Oslo: 
Norwegian Institute of Public Health; 2012. Available at: www.whocc.no. 
b. Polk RE, Fox C, Mahoney A, et al. Measurement of adult antibacterial drug use in 130 U.S. hospitals: comparison of defined daily dose and days of 





Ø 2D RESOURCE: Does Choice of Control Group Affect the Association of Antibiotics 
With Clostridium difficile-Associated Diarrhea? 
Purpose: A poster showing the process of describing if choice of control group affects the 
association of antibiotics with Clostridium difficile-associated diarrhea. 
Source: Developed by P. Chung, Y. Gao, and B. Ostrowsky, Montefiore Medical Center, for 
2011 Society for Healthcare Epidemiology of America annual meeting. Abstract available 
at: http://shea.confex.com/shea/2011/webprogram/Paper4443.html. 
Instructions: Use as a reference. 
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Ø 2E RESOURCE: Sample Tracking and Summary Forms for Case-Control Study  
Purpose: A tool to track and organize comparisons of antibiotic exposures in a case-
control study to identify potential antibiotic targets associated with C. difficile. 
Source: Adapted from ERASE C. difficile Project. 
Instructions: Electronic form formatted in Excel. Use this form to enter data. Select each 
field, enter the data, and use “Save as” to save your facility’s data. 
 











Ø 2F RESOURCE: Comparison of Potential Antimicrobial Stewardship Interventions, With an Emphasis on Reducing C. difficile1 
Purpose: A tool to review types of antimicrobial stewardship interventions, comparing strengths and weaknesses and providing examples. 
Source: Developed by B. Ostrowsky and S. Brown, Montefiore Medical Center, for ERASE C. difficile Project toolkit. 
Instructions: Use when choosing and implementing targeted interventions. 
Intervention Type
1,2




 Effective in decreasing targeted 
antibiotics 
 Can influence choice of antibiotics 
before patients receive therapy 
 Has education built into process of 
discussing therapy choice 
 Less evidence as a means of reducing 
long-term antimicrobial use or 
outcomes, such as resistance 
 May shift prescribing to alternative 
agents (e.g., ―squeezing the balloon‖) 
and resulting resistance/C. difficile 
 Effectiveness dependent on skills of 
staff making recommendations and 
reviewing requests 
 Mainly affects initial regimen choice and 
not length of treatment 
 May be less acceptable to prescribers 
(viewed as policing antibiotics) 
 May involve delays in therapy (to obtain 
approval) 
 Restricting empiric use of antibiotics 
associated with most C. difficile cases 
(may be whole hospital, for specific 
patient populations/prescribers) 
 Choosing specific drugs for the formulary 
(e.g., limit multiple/redundant quinolones, 
carbapenems) 
 Mandating Infectious Diseases 
consultation for specific drugs 
Audit and feedback to 
providers, including 
strategies for de-escalating 
and streamlining antibiotics 
 Has been shown to improve 
antimicrobial use and outcomes 
 Can be adapted to many hospital 
environments (including small 
facilities or facilities with limited 
resources) 
 Can be done a few times per 
week 
 Facilitates a team approach to 
patient care 
 Allows intervention in cases of 
inadequate therapy 
 Allows flexibility of therapy based 
on patient response and clinical 
status 
 Labor intensive; effectiveness 
dependent on skill of staff making the 
recommendation 
 Need systems in place to identify 
patients on whom intervention can be 
done (helpful to have information 
technology [IT] or computer software 
support) and how best to convey 
suggestions to prescribers (e.g., verbal, 
written in medical record) 
 Mainly affects length of treatment 
(depending on when performed, may 
have variable impact, especially if 
patients have been on antibiotics for 
long periods of time) 
 May be less acceptable to prescribers 
(viewed as interfering with prescribing) 
 Obtaining lists of patients on extended 
spectrum β-lactams and third/fourth 
generation cephalosporins at 72 hours 
and approaching clinicians after chart 
review for de-escalating antibiotics 
 Targeting cefepime-containing empiric 
therapy in ICU patients with daily rounds 
with ICU teams (identifying opportunities 







 Advantages Disadvantages Examples 
Flow and algorithms for 
empiric and streamlined 
regimens for specific 
diagnoses or pathogens 
 Improves prescribing, including 
adapting national guidelines to 
local microbiology and population 
 Can be multidisciplinary in 
development  
 Can affect initial antibiotic choice 
and further tailoring of antibiotic 
 Requires an outlay of effort over time to 
develop and educate in their use  
 Needs to be appropriately disseminated 
and accepted  
 Needs to be an agreement on therapy 
by all involved parties  
 Protocols for workup and/or empiric 
regimens for sepsis, community-acquired 
pneumonia, and urinary tract infections 
Novel approaches to use 
of technology and 
stewardship staff  
 Allows interventions to be tailored 
to unique populations and local 
microbiology  
 Broadens pool of resources for 
stewardship activities 
 Allows use of local systems to 
obtain data and supplement 
activities  
 Shorter track record and less ability to 
predict impact  
 Outlay of effort by stewardship team 
and others (e.g., IT)  
 Technology  costs 
 
 Training clinical pharmacists, pharmacy 
residents, and infectious disease fellows 
to prescreen candidates for de-escalation 
or streamlining initiatives 
 Involving nursing and nursing leadership 
(―non‖ prescribers) in stewardship 
activities 
 Using pharmacy tools, including 
automated pharmacy technology (e.g., 
Pyxis Medstation™) to offer and track 
antibiotic prescribing in the emergency 
department  
Educational component for 
clinicians and patients 
 Necessary for prescriber buy-in 
and prescribing in general 
 Supplements above activities  
 Have been less successful on their 
own; should be coupled with other 
interventions 
 Case-based learning, including how to 
use algorithms and when and how to de-
escalate antibiotics 
 Lectures on antibiotic use 
1. Traditional methods such as intravenous to oral switch programs and dose optimization may be used by a well-rounded antimicrobial stewardship team, but on 
their own will likely not be effective interventions directed at decreasing C. difficile infection.  
2. Categories adapted from  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional 






Ø 2G RESOURCE: A Review of Antimicrobial Stewardship Interventions With Suggested Process/Monitoring, Antibiotic Use, and 
Additional Measures of Impact  
Purpose: A tool to review types of antimicrobial stewardship interventions, comparing process measures, antibiotic metrics, and other 
factors to track. 
Source: Developed by B. Ostrowsky and P. Chung, Montefiore Medical Center, for ERASE C. difficile Project toolkit. 




Possible Antibiotic Use Measures To Access 
Impact 






 Number of calls/requests for 
restricted drug (changes over time) 
 Percentage of requests approved 
(over time by staff) 
 Number of formal Infectious Diseases 
consultations 
 Total number of courses or patients on restricted 
antibiotics, alternative antibiotics to the restricted 
drug 
 Defined daily doses  
 Time to receipt of antibiotics 
(delays) 
 Number of doses 
dropped/missed 
 Antibiotic costs  
Audit and feedback to 
providers  
 Number of patients who met criteria 
for auditing, reviewed, advice given, 
intervention made, and advice 
accepted 
 Number of formal Infectious Diseases 
consultations 
 Days of therapy for antibiotics and total patients 
on redundant antibiotic combinations  
 Defined daily doses 
 Length of stay 
 Clinical failure—reinstitution of 
broad antibiotic regimens  
 Readmissions 
 Antibiotic costs 
Flow and algorithms for 
empiric and streamlined 
regimens for specific 
diagnoses or pathogens 
 Web hits for educational pages with 
algorithms 
 Educational assessment of 
understanding of guidelines 
 By limited chart/patient review—
percentage of patients 
receiving/tailoring antibiotics per 
protocols 
 Total number of patients with syndrome or 
diagnosis on appropriate antibiotics (may have 
external validated measure such as Centers for 
Medicare & Medicaid Systems [CMS] core 
measures, e.g., pneumonia) 
 Total number of courses or patients on 
antibiotics and duration of antibiotics involved in 
protocol  









Possible Antibiotic Use Measures To Access 
Impact 
Additional Measures, Including 
Benefits/Unintended 
Consequence 
Antibiotic order forms 
and automatic stop 
orders 
 Number of patients per month where 
antibiotic form used 
 By limited review—percentage of 
patients where antibiotic order form 
was used, e.g., to continue or stop 
antibiotics  
 Total number of patients with syndrome or 
diagnosis on appropriate antibiotics or for 
appropriate length (may have external validated 
measure such as CMS core measures for 
surgical prophylaxis) 
 Total number of courses or patients on 
antibiotics and duration of antibiotics involved in 
the automatic orders (may be by service, 
prescriber, patient population, or forms/order)  
 
Novel approaches to 
use of technology and 
stewardship staff 
 Will depend on nature of intervention  
 Number of calls, requests, or 
interventions by specific staff 
(percentage acceptance rates) 
 Number of patients per 
month/timeframe where technology 
used  
 Will depend on nature of intervention 
 Comparison of specific antibiotic courses before 
and after intervention 
 Will depend on nature of 
intervention 
Educational component 
for clinicians and 
patients 
 Number of educational programs 
 Number of attendees 
 Survey of attitudes or understanding 
about prescribing topic 
 Will depend on nature of education 
 Total number of courses or patients on 
antibiotics and duration of antibiotics involved 
 Improved visibility of program 
 Collaborative care or 
camaraderie with other services 
 Possible exchange of ideas 
about processes and choice of 
therapy 
1. Traditional methods such as intravenous to oral switch programs and dose optimization may be used by a well-rounded antimicrobial stewardship team, but on 
their own will likely not be effective interventions directed at decreasing C. difficile infection.  
2. Categories adapted from Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional 






Ø 2H RESOURCE: Specific Intervention Examples From ERASE C.  difficile Project 
Purpose: Overview of implemented antimicrobial stewardship by ERASE C. difficile participants. Describes examples of antimicrobial 
stewardship interventions implemented by six participating facilities in ERASE C. difficile Project, including details of activities, timeframes, 
locations, and stewardship staffing or activities. 
Source: Adapted from ERASE C. difficile Project by H. Jalon, United Hospital Fund, and B. Ostrowsky, Montefiore Medical Center. 
Instructions: Use as a reference. 
Facility 
Description Interventions Start Date Location Notes/Comments 
481-bed teaching 
hospital 
Specific programming of 
antibiotic stewardship 
computer software to 
identify patients with longer 
antibiotic lengths (> 14 days) 
Approximately 1 year Hospitalwide  Overall issue with staffing (no infectious disease 
fellows). 
 For IV to oral, computer prompt done at 3-day 
mark for fluoroquinolones. 
 Antibiotic policy change catalyzed by patient 
experience; very new official policy, but education 
started September 2011. 
 Had intended to target piperacillin/tazobactam, 
including de-escalation; more opportunities with 
ciprofloxacin.  
 Ciprofloxacin policy verbalized in September-
November 2011 and officially implemented in 
December 2011. 
Clinical computer prompts 
IV to oral switch (asks for 
indication) 
July 2011 Hospitalwide 
Antibiotic change policy 
away from ciprofloxacin for 
urinary tract infections 
September-November 2011 ER(ED), then 






August 2010 Hospitalwide  Overall limited resources (pharmacist part time); 
activities sporadic some months. 
 Piperacillin/tazobactam restriction (mainly by 
infectious disease fellows) saved money; push 
toward cefepime/ceftriaxone; main outcome 
number of courses. 
 Background—auditing, de-escalation, days of 
therapy/defined daily dose. 
Audit and feedback Ongoing (predates ERASE 









Description Interventions Start Date Location Notes/Comments 
709-bed teaching 
hospital, with two 
sites (each similar 
size): Activities at 
Site 1  
Piperacillin/tazobactam 
restriction (many years old) 
Ongoing (predates ERASE 
C. difficile Project) 
Hospitalwide  ASP and infection control activities ongoing prior 
to ERASE C. difficile Project; resulted in 
significant decrease in C. difficile rates.  
 Overall staffing problems (PharmD for both 
hospital sites, used pharmacy residents). 
 Audit/feedback (pharmacy residents with 
PharmD—both campuses): educational 
component in ICU to reduce cefepime use, 
infectious disease guidance, days of 
therapy/defined daily dose (infectious disease 
attending with ICU, primarily at one site). 
Reemphasized beginning July 2011. 
Audit and feedback (de-









hospital, with two 
sites (each similar 
size): Activities at 
Site 2 
Piperacillin/tazobactam 
restriction (many  
years old) 
Ongoing (predates ERASE 
C. difficile Project) 
Hospitalwide 
Audit and feedback (de-








targeting efepime use 
specifically in ICU 
January 2011 MICU (7EM Medical) 
1,038-bed teaching 
hospital, with two 




Azithromycin restriction April-May 2011 Hospitalwide  More interventions overall done at one of the two 
sites. 
 Azithromycin first restricted, then unrestricted to 
move patients away from moxifloxacin; formal 
medication utilization review for fluoroquinolones 
(ciprofloxacin and moxifloxacin). 
 Followup  medication utilization review showed 
increase in azithromycin and decrease in 
moxifloxacin (by 25%) at both campuses. 
 Piperacillin/tazobactam audit mainly on medicine 
services (teaching and nonteaching services). 
 Education in conjunction with interventions (series 
of educational programs to different clinical  
services showing C. difficile rates, data, and 
teaching about de-escalation). 





Pilot (with infectious 
disease fellow): February-
April 2011  
Increased activity 






Klau and NW 




hospital, with two 








Pilot (with infectious 
disease fellow): February-
April 2011  
Increased activity 









Ø 3G/3H RESOURCES: Environmental Cleaning and Infection Prevention Checklists 
Purpose: Examples of tools that participating facilities used to train and track compliance 
with environmental cleaning infection prevention practices. 
Source: Adapted from GNYHA/UHF C. difficile Collaborative. 
Instructions: Could be used as template for development of similar tool to be used at 







Ø 4A TOOL: How Do We Sustain ASP for Reducing C difficile Over Time? 
Purpose: To help assess systems currently in place and ability to maintain and sustain ASP 
over time.  
Source: ERASE C. difficile Project team. 
Instructions: Complete checklist, review responses to ascertain the level of leadership 
support, and consider which areas need strengthening to move forward. 
1. Will our current ASP staffing work on an ongoing 
basis? 
How well is your stewardship team working across 
departments and disciplines? What is the current distribution 
of responsibilities? Do you need to make changes? 
Action/remedy/plan if needed: 
Who are the staff dedicated 






Is this sustainable? 
 yes  no 
If Yes, describe: 
 
 
If No, what is the plan to make this 
sustainable? 
What is the 
rotation/schedule for 
residents and fellows? 
Describe: 
 
Is this sustainable? 
 yes  no 
If Yes, describe: 
 
 




Is our ASP hospital wide?  yes  no  
If No, describe the scope of 
the program: 
If No, describe where implemented: 
How do we maintain inter-
disciplinary communication? 
Describe processes [committees, meetings, etc.]: 
What are ASP members’ 
responsibilities? 
Describe: 
Is the distribution of 
responsibilities fair? 
 yes  no If No, describe changes needed: 
Do we need to make 
changes? 





2. What is the plan for ongoing measurement and 
feedback?  
A plan is only as good as the systems in place that ensure 
sustainability. It is crucial to plan at the onset for ongoing 
monitoring, maintenance, and evaluation of the ASP for 
reducing C. difficile 
Action/remedy/plan if needed: 
Do we have a plan for 
monitoring the ASP? 
 yes  no 
If Yes, describe: 
If No, what should the plan be? 
Do we have a plan for 
maintenance of the ASP? 
 yes  no 
If Yes, describe: 
If No, what should the plan be? 
Do we have a plan for 
evaluation of the ASP? 
 yes  no 
If Yes, describe: 
If No, what should the plan be? 
Are our data in a workable 
format? 
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain? 
What are our current IT 
systems, staffing, and 
capabilities? 
Describe:  
Do we have appropriate IT 
software? 
 yes  no 
If Yes, describe: 
 
If No, what is the plan to obtain? 
3. What ongoing organizational support will be needed to 
keep the new ASP practices in place? 
Maintaining your ASP requires organizational support on 
multiple levels. Ongoing organizational support for ASP for 
reducing C. difficile will be strongest if you can demonstrate 
that it is aligned with the medical center’s strategic priorities 
and that it addresses pressing problems.  
Action/remedy/plan if needed: 
Is there organizational 
support for ASP?  
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain? 
Do we have the resources to 
maintain adequate and 
dedicated ASP staffing?  
 yes  no 
If Yes, describe:  
If No, what is the plan to obtain? 
Do we have the appropriate 
IT support to produce the 
most useful data?  
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain? 
Do we have educational 
opportunities and forums to 
keep staff current on our 
ASP practices? 
 yes  no 
If Yes, describe: 
If No, what is the plan to provide? 
Do we have systems in 
place to maintain best 
practices for ASP?  
 yes  no 
If Yes, describe: 
If No, what is the plan to maintain? 
Do we have clinical 
leadership support for ASP?  
 yes  no 
If Yes, describe:  
If No, what is the plan to obtain? 
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Do we have medical center 
leadership for ASP? 
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain? 
Does ASP fit in the 
hospital’s overall-strategic 
planning?  
 yes  no 
If Yes, describe: 
If No, what is the plan to include ASP 
in strategic planning? 
4. How do we develop an effective business case?  
Given the environment of tightening resources in most 
medical centers, you will likely need to make a strong 
business case for continued or expanded investment in your 
ASP to include C. difficile.  
Action/remedy/plan if needed: 
Are there financial barriers 
to implementing ASP? 
 yes  no 
 
If Yes, describe: 
Do we have a good estimate 
of cost savings realized 
through full implementation 
of ASP? 
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain 
estimates? 
Have we calculated 
anticipated savings? 
 yes  no 
If Yes, describe: 
If No, what is the plan to obtain? 
Have we calculated actual 
savings? 
 yes  no 
If Yes, describe: 
If No, what is the plan to calculate? 
Do we have a description of 
how ASP activities translate 
into cost savings? 
 yes  no 
If Yes, describe: 
If No what is the plan to create a 
description? 
Do we have a description of 
how improved patient 
outcomes bring about cost 
savings? 
 yes  no 
If Yes, describe: 





Please note: The following three tools are examples developed by facilities participating in 
the ERASE C. difficile Project to implement interventions. 
Ø 4B TOOL: UTI Guidelines Form 
Purpose: Urinary tract infection (UTI) treatment guidelines. Gives background, local 
microbiology data, and suggested empiric regimens. 
Source: F. Palmieri, Bronx-Lebanon Hospital. 
Instructions: Review and adapt as appropriate. 
 
 
Empiric Therapy Regimen 
Acute Uncomplicated Cystitis 
Antibiotic 
Recommendations Caution Duration 
Possible Side Effects 
(selected) 
Nitrofurantoin (Macrobid) 
100 mg twice daily  
Do not use if CrCl < 60.  
Do not use for elderly 
patient > 65 years old. 
Do not use during 
pregnancy at term (38 to 
42 weeks gestation). 
Caution in cholestatic 
jaundice and hepatic 
dysfunction. 






hemolytic anemia in G6PD 
deficiency 
Cefuroxime 250 mg oral 
q12h  
Avoid in penicillin allergy.  
If CrCl < 10mL/min, 
administer once daily. 
7 days Anaphylaxis (PCN allergic); 
diarrhea; other super 
infections; eosinophilia; 
positive Coombs test; 
interstitial nephritis; 
hemolytic anemia 
Cefpodoxime 100 mg oral 
q12h  
Avoid in penicillin allergy.  
If CrCl < 30mL/min, 
administer once daily. 
7 days As above 
Ciprofloxacin 250 mg oral 
q12h - 3rd line therapy due 
to resistance. If selected, 
urine culture with followup is 
recommended. 
If CrCl < 30mL/min, 
administer once daily. 
5 days C. difficile colitis; QTc 
prolongation; nephritis; 
tendon rupture; neuropathy 
Acute Uncomplicated Pyelonephritis  
Antibiotic 
Recommendations Caution Duration 
Possible Side Effects 
(selected) 
Initial Therapy 








As above for cefuroxime 
plus pseudocholelithiasis 
Gentamicin IV 3 mg/kg x1 
dose 
No adjustment for initial 





Followup Therapy – Tailor Therapy to Culture and Sensitivity Report; Otherwise: 
Ciprofloxacin 500 mg oral 
q12h 
As above 7 to 14 
days 
As above 
Cefuroxime 250 mg oral 
q12h 
As above 7 to 14 
days 
As above 
Cefpodoxime 200 mg oral 
q12h 









Bronx Lebanon Hospital Center 
1650 Grand Concourse 
Bronx, New York 







 Escherichia coli constituted 91 percent of 
community-acquired urinary isolates in the 
past year in BLHC. 
 Bacterial resistance to 
sulfamethoxazole/trimethoprim (SMZ/TMP) 
and fluoroquinolones has increased.  
 Urine culture and susceptibility (C & S) tests 
are strongly recommended for any therapy 
changes.  
 Modify therapy according to BLHC UTI 
guidelines. 
 Do not use SMZ/TMP as empiric therapy 
or ciprofloxacin as initial therapy due to 
high resistance to E. coli.  
 
 
















STEP 1: Urinalysis 
 Urinalysis (UA) 
 Urine micro 
 Urine culture 
o Before antibiotics are started 
o For ED patients  
o Inpatients with UTIs 
o All patients with suspected 
pyelonephritis 
STEP 2: Empiric Antibiotics 
 See table on back. 
STEP 3: Pathogen-Directed Therapy 
 With culture and susceptibility results, 
change antibiotic to pathogen-specific 
agent. 
 Follow up on all discharged patients to 
provide appropriate therapy based on 
culture and sensitivity results. 
 SMZ/TMP can be used at this point as 
dictated by the C & S results. 
 Reserve fluoroquinolones for 
pyelonephritis and major systemic 
infections due to resistance 
development. 
STEP 4: Duration 
 As important as the therapy itself. 
 Excessive use can lead to:  
o Adverse reactions.  
o Increased antimicrobial resistance. 
 See table on back for specific duration 
recommendations. 
 
STEP 5: Epidemiologic Surveillance 
 With time and selective pressure, 
resistance patterns will change. 
 At least once a year, susceptibility 
patterns will be reassessed and the 
need to change treatment 
recommendations evaluated. 
ASYMPTOMATIC BACTERIURIA 
 Asymptomatic bacteriuria is defined as 
isolation of a specific quantitative count of 
bacteria in an appropriately collected urine 
specimen from an individual without sign or 
symptoms of a urinary tract infection. 
 Avoiding treatment of asymptomatic 
bacteriuria is important for reducing the 
development of antibiotic resistance.  
 Treatment of asymptomatic bacteriuria is not 
appropriate for: women (premenopausal, 
nonpregnant), diabetics, elderly people, 
nursing home residents, or patients with 
spinal cord injury or indwelling urethral 
catheters. 
 Treatment of asymptomatic bacteriuria is 
appropriate for pregnant women and for 
patients undergoing urologic procedures in 
which mucosal bleeding is expected. 
 
REFERENCES 
1. Gupta K, Hooton TM, Naber KG, et al. 
International clinical practice guidelines for 
the treatment of acute uncomplicated cystitis 
and pyelonephritis in women. A 2010 update 
by the Infectious Diseases Society of America 
and the European Society for Microbiology 
and Infectious Diseases.Clin Infect Dis 
2011:52(5):e103-20. Review. 
2. Nicolle LE, Bradley S, Colgan R, et al Infectious 
Diseases Society of America guidelines for the 
diagnosis and treatment of asymptomatic 







Ø 4C TOOL: Pipercillan/Tazobactam De-Escalation Form 
Purpose: Forms for tracking piperacillin/tazobactam audit/feedback. The tracking forms 
give a way to track number of patients with criteria for review and then a way to document 
stewardship interventions. 
Source: Y Guo & B. Ostrowsky, Montefiore Medical Center. 
Instructions: This 2-page form may be tailored for possible use at your facility; review and 
adapt as appropriate. 
 
From the Antimicrobial Stewardship Program, Montefiore Medical Center 
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ANTIMICROBIAL STEWARDSHIP TEAM (AST) SUGGESTIONS 
1. Run/obtain daily list of piperacillin/tazobactam utilization report. 
2. Select patient who has been on piperacillin/tazobactam for >72 hours without ID 
consult. 
3. Review Carecast/chart for indication, duration, culture susceptibility, etc., to determine 
the appropriateness of piperacillin/tazobactam usage. 
Date:  _________________________  
Total number of patients who have been on piperacillin/tazobactam:  ________________________  
Total number of patients who have been on piperacillin/tazobactam for >72 hours:  ________  
Total number of patients who have been on piperacillin/tazobactam >72 hours with ID 
consult  ______________________  
Total number of patients who have been on piperacillin/tazobactam >72 hours without ID 
consult  ______________________  
From patients who have been on piperacillin/tazobactam >72 hours without ID consult, 


















Developed by Y. Guo and B. Ostrowsky. Piperacillin/tazobactam de-escalation form 
 
From the Antimicrobial Stewardship Program, Montefiore Medical Center 
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Date:  _________ Patient name:  ________________________  MR# __________  Unit/room _______  
Presumptive diagnosis: 
 Culture documented pseudomonas/gram negative resistant infection 
o Site of documented culture  ________________________________  
 Healthcare-associated pneumonia (continued empiric coverage) 
 Healthcare-associated intra-abdominal infection (continued empiric coverage) 
 Healthcare-associated urinary tract infection (continued empiric coverage) 
 Necrotizing soft tissue infection (not cellulitis) (continued empiric coverage) 
 Other healthcare-associated sepsis/infection. List syndrome  ______________________________  
 Other. List syndrome  ___________________________________________________________________________  
 
Piperacillin/tazobactam (dose/frequency/duration) 
 ________________________________________________________________________________________________________  
Based on information available, we suggest the following modifications to your patient’s 
antimicrobial therapy. 
1.  ____________________________________________________________________________________________________  
2.  ____________________________________________________________________________________________________  
3.  ____________________________________________________________________________________________________  
 
These changes are recommended based on: 
 Culture/sensitivity data 
 Drug toxicities/side effects 
 Opportunity to change to  oral 
therapy 
 More narrow spectrum antibiotic regimen 
 Specific diagnosis 
 Others: ___________________________________________  
 
 
Notes left in the chart: 
 Yes   No 
Did the team accept your recommendation? 
 Yes   No 
If a thorough analysis of this case is desired, please request an ID consultation. 





Ø 4D TOOL: Medication Use Evaluation Template  
Purpose:  A template for reviewing use patterns, including graphic comparison over time. 
Source: S. Brown & B. Ostrowsky, Montefiore Medical Center. 
Instructions: This template may be tailored for possible use at your facility; review and 
adapt as appropriate. 
MEDICATION USE EVALUATION 
Unit/Area: XXX Medical Center (XXX Campus) 
Submitted by: Antibiotic Stewardship Program 
Title: Oral Azithromycin Utilization Evaluation 
Date: XXX 
======================================================================== 
INDICATORS: (1) Usage and mean duration of oral azithromycin before and after 
unrestriction; and (2) whether there is a decrease in quinolone use before and after 
unrestricting azithromycin.  
PLAN 
Disciplines Involved: Antibiotic Stewardship Program 
Monitoring Period: XXX – XXX 
Sample Size: XXX patients at Campus and XXX patients at Campus according to SYBASE 
query listing.  
Methodology: Retrospective reviews of antibiotic usage were conducted in patients who 
received oral azithromycin from XXX to XXX. The total numbers of patients on oral 
azithromycin, ciprofloxacin, moxifloxacin, and various other antibiotic combinations (i.e., 
azithromycin plus ceftriaxone, piperacillin/tazobactam, ciprofloxacin, or moxifloxacin) 
were calculated. Analyses were conducted to determine the usage and mean duration of 
oral azithromycin before and after unrestriction.  
DO 
Reports were generated using the SYBASE query listing all patients who received oral 
azithromycin, ciprofloxacin, moxifloxacin, piperacillin/tazobactam, and ceftriaxone 
between XX and XX.  
CHECK 





 Month Month Month 
Campus 
Mean duration of azithromycin 
(range), days of therapy 
X (Y-Z) X (Y-Z) X (Y-Z) 
Antibiotics Number of Patients 
Azithromycin PO XX XX XX 
Moxifloxacin PO XX XX XX 
Ciprofloxacin PO XX XX XX 
Campus 
Mean duration of azithromycin 
(range), day 
X (1-X) X (1-X) X (1-X) 
Antibiotics Number of Patients 
Azithromycin PO XX XX XX  
Moxifloxacin PO XX XX XX 
Ciprofloxacin PO XX XX XX 
Table 2. Azithromycin PO and Ceftriaxone 
 Month Month Month 
Campus 
Number of patients  XX  XX XX 
Duration of azithromycin 
(range), day 
X (1-X) X (1-X) X (1-X) 
Campus 
Number of patients  XX  XX XX 
Duration of azithromycin 
(range), day 
X (1-X) X (1-X) X (1-X) 
Table 3. Number of Patients on Azithromycin PO and Moxifloxacin 
 Month Month Month 
Moses XX XX XX 
Weiler  XX XX XX 
Table 4. Number of Patients on Azithromycin PO and Ciprofloxacin 
 Month Month Month 
Moses XX XX XX 
Weiler XX XX XX 
Table 5. Number of Patients on Azithromycin PO and Piperacillin/ tazobactam 
 Month Month Month 
Moses XX XX XX 




Figure 1. Comparison of Oral Azithromycin and Quinolone Usage at Campus, Before Unrestriction 
 
Figure 2. Comparison of Oral Azithromycin and Quinolone Usage at Campus, After Unrestriction 
 
ACT 
 There was a trend of XX oral azithromycin usage comparing XX to XX after 
unrestriction.  
 There was a trend of decreasing oral moxifloxacin usage comparing XX to XX; however, 
it might be an artifact of seasonal change. Comparing XX to XX, the total number of 
patients on oral moxifloxacin did not change significantly.  
 The antibiotic stewardship program will continue to monitor oral azithromycin usage 
via pharmacist/house staff education on duration of therapy and prevent double 
atypical coverage for asthma, chronic obstructive pulmonary disease, or community-

























Azithromycin PO Moxifloxacin PO Ciprofloxacin PO 
